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Abstract
The current trend in magnetic resonance imaging (MRI) is towards higher external
magnetic field strengths (B0) to take advantage of increased sensitivity and signal to noise
ratio (SNR). Unfortunately, as B0 increases the effectiveness (relaxivity) of clinical
gadolinium (Gd3+)-based contrast agents (CAs) administered to enhance image contrast is
significantly reduced. Excellent soft tissue contrast can be generated with current agents
despite their non-optimum relaxivities but necessitates large doses.

The limits of

detection of a CA at high B0 fields can be lowered by recovering the lost relaxivity and is
a pre-requisite to the goal of molecular imaging in which CAs are bound to biomarkers of
pathology that exist at very low concentrations. Traditional methods for increasing the
detectability of CAs have focused on optimizing critical parameters identified from the
Solomon-Bloembergen-Morgan (SBM) theory that affect relaxivity.

Gains in relaxivity

with these methods to date have been modest and are far from the theoretical maximum
possible. Although researchers continue to investigate novel complexes that provide
improved relaxivities, any such complex would require a lengthy and costly approval
process with the U.S. Food and Drug Administration (FDA). Therefore, a method that
affords improved relaxivities of current clinically approved CAs, particularly at high B0
fields, that could be adopted into clinical practice rapidly, is of great interest.
Spin locking is a nuclear magnetic resonance (NMR) technique that was introduced for
imaging in 1985, but has received very little attention in combination with Gd3+-based
CAs. The technique employs a low power long duration radiofrequency (RF) pulse (B1)
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parallel to the net magnetization in the x,y-plane. This locks the magnetization into lower
precessional frequencies around an “effective” field (Beff) that is reduced with respect to
B0 but maintains the high field advantages required for imaging. When considered in the
rotating frame, longitudinal relaxation of the magnetization against Beff exhibits shorter
time constants (T1ρ) expected at these lower precessional frequencies. This leads to
higher relaxivities, which has implications for increasing CA detectability.
The experiments described herein show that rotating frame longitudinal relaxivities (r1ρ)
for current clinical Gd3+-based CAs are essentially independent of the strength of the spin
lock pulse (γB1) as predicted by theory. This result is important because it allows the
value of γB1 to be neglected when comparing r1ρ of Gd3+-based CAs across several B0
fields. The magnetic field dependence of r1ρ for all clinical agents showed that relaxivity,
lost by moving to higher fields, could be “recovered” and that r1ρ was sensitive to the
rotational correlation time constant (τR) of the agent. Using high molecular weight
Nanoassembled capsules (NACs) containing a Gd3+-based CA to probe this finding
further, we were able to generate relaxivities at high field up to an order of magnitude
greater than clinical agents at current imaging fields.

These are beyond anything

previously reported, or likely to be, with current techniques. Finally, we demonstrated
that by spin locking Mn2+ agents, relaxivities at high field increased by a factor of ~ 30
than without spin locking, due to their larger dependence on scalar coupling. These
findings show the potential of spin locking to increase detection limits dramatically at
high field and are an exciting development towards the goal of molecular imaging.
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CHAPTER 1. INTRODUCTION
1.1. Magnetic resonance imaging: a critical imaging mode of the past, present and
future
1.1.1. The rise to popularity of MRI
In 1938 Isidor Rabi conducted the first nuclear magnetic resonance (NMR) experiments
on Lithium chloride in his laboratory at Columbia University.1 In 1946, and within a
month of each other, teams at Harvard, lead by Purcell,2 and Stanford, lead by Bloch,3
had refined the technique and independently made observations of weak magnetism of
protons in condensed matter. Awarded the Nobel Prize in physics for their work these
were the founding fathers of NMR, which has since found many applications. One such
application is magnetic resonance imaging (MRI). In 1973 Paul Lauterbur demonstrated
the imaging potential of MR by differentiating heavy and normal water in-vitro.4

The

utility of such a technique was quickly recognized and the push towards the ultimate goal
of imaging a living human began. In the late 1970’s, shortly after Lauterbur’s discovery,
in-vivo images of the human finger5 and whole body imaging6 were published. Since,
many technological advances including: cryogenic magnets, Gadolinium contrast agents,
actively shielded magnets and the emergence of stronger magnetic fields for routine
imaging to name just a few, have led to the current state of development of clinical MRI.7

CHAPTER 1. Introduction
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1.1.2. Modern day MRI and its comparison with other imaging modalities
During this time, MRI has steadily become established amongst other imaging modalities
available to radiologists including: X-ray, computed tomography (CT), ultrasound (US)
and positron emission tomography (PET). Since the first commercial system in 1983
~20,000 MRI systems have been installed worldwide7 with ~27 million scans (half the
number of X-ray scans) being performed in the US alone in 2007.8 The popularity of
MRI can largely be attributed to the technique being relatively non-invasive, employing
non-ionizing radiation and having the ability to measure whole tissue samples with
exceptional soft tissue spatial resolution and contrast, albeit at the expense of imaging
time. However, the real power of MRI is in its flexibility. MRI has the ability to
characterize several tissue parameters that can vary from tissue to tissue, allowing it to
distinguish between healthy and diseased tissue and identify key markers of many
diseases and disorders including those most prevalent in human kind.9-13 Moreover, this
can be achieved whilst keeping the hardware required relatively constant and presenting
clinically relevant information as easy-to-interpret 3D digital contrast images based on
signal intensity. The signal in an MR image is typically generated from the water proton
nuclei, the most abundant nuclei in vivo, maximizing the technique’s sensitivity. Despite
this, the sensitivity of MRI remains poor in comparison to X-ray-based methods, PET
and US. However, MRI offers the advantage of fewer safety concerns. Although US is
also considered very safe and the sound waves employed afford excellent temporal
resolution, its drawback comes from poor spatial resolution. As can be imagined, for
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accurate diagnosis and optimal treatment of disease a combination of these
complimentary imaging modalities is often required.
1.1.3. The future of clinical MRI
The major drawback for MRI is the technique’s lack of sensitivity which is related to the
field strength (B) of the magnet, measured in flux density (tesla, T).

Since the

introduction of NMR in the 1960’s, and later MRI, the operating magnetic field strength
for both has increased linearly over time, leading to small incremental gains in
sensitivity.14

The vast majority of clinical scanners today operate at 1.5 and 3 T,

however, many 4.7 T scanners are in preclinical use and human imaging is permitted up
to 8 T.7 There is no evidence to suggest that the current trend is about to change and as
such larger magnets will dot the landscape in the not so distant future. At these high
fields, scientists seek to further lower detection limits and increase spatial resolution as a
result of the improved signal-to-noise ratio (SNR).15 For as long as there is both a
clinical and commercial requirement for larger magnets, any technological challenge
imposed shall be met. Such challenges to large magnets include, but are not limited to:
instrument siting within current radiology departments, B0 field homogeneity across large
bore instruments and economics of the setup and running costs.
1.2. Nuclear magnetic resonance (NMR) theory
Although much of what follows is in the context of MR imaging, the theories are entirely
grounded in those of NMR. Thus, it is important to be reminded of the underlying
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physics, the origin of the signal as it pertains to MRI and its detection for contrast
generation.
1.2.1. The Zeeman effect
Atoms comprise of electrons and a positively charged nucleus containing protons and
neutrons. Interactions between the nuclei of many isotopes and the magnetic fields that
surround them, allows NMR to provide detailed molecular information. Fundamental to
NMR is spin, a physical property of all nuclei. Spin is a purely quantum mechanical
concept that can be represented by the classical vector model of angular momentum.
However, unlike classical angular momentum, induced by rotation, spin angular
momentum is an intrinsic property.

The total spin angular momentum, I, a vector

quantity, is given by Equation 1.1 where ħ is the reduced Planck’s constant (Planck’s
constant divided by 2π) and I is the specific spin quantum number of the nuclei of
interest, a positive multiple of ½.
=ħ

+1

(1.1)

Isotopes with even mass numbers and even numbers of both protons and neutrons (e.g.
12

C6) posses a spin quantum number (I) of zero and therefore no angular momentum and

are NMR inactive. However, if the proton and neutron numbers are both odd (e.g. 2H1
and

14

N7) I takes non-zero integer values. Isotopes with odd mass numbers and either

odd or even numbers of protons and neutrons, such as the main isotope of hydrogen (1H1)
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and the minor stable isotope of carbon (13C6), posses half-integer spin values. Isotopes
with non-zero spin values posses angular momentum and are NMR active.
With respect to an arbitrarily chosen axis, shown projected with respect to the z-axis in
Equation 1.2, the spin vector of the angular momentum can have several possible
directions, a result of the quantized nature of the spin projection magnetic quantum
number, mI, for which quantum mechanics dictates there are 2I+1 possible values which
range from –I to +I with integer steps.
=

ħ

(1.2)

The angular momentum of the nuclei gives rise to a nuclear magnetic moment (µ)
proportional to the total spin angular momentum (I) and the gyromagnetic ratio (γ), a
constant specific to the nuclei of interest (Equation 1.3).
=

(1.3)

The magnetic moment of the proton creates a weak magnetic field that interacts with
local magnetic fields. In MRI, the nucleus of interest is that of the abundant water proton
(1H1) which has a spin quantum number (I) of a ½ and therefore two possible spin
projection quantum numbers (mI) of -½ and +½. In the absence of an external magnetic
field these two spin states have equal probability and therefore equal spin populations and
are considered energetically degenerate. As a consequence of this degeneracy the total
magnetic moment is zero.

When a subject is immersed in the strong homogenous

magnetic field (B0) of an MRI instrument two interesting processes occur simultaneously.
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One, the degeneracy of the two spin states is broken and the proton nuclei can either align
parallel to B0, denoted as +½ (low energy, α), or anti parallel to B0, denoted -½ (high
energy, β). This is known as the Zeeman effect, where the energy is the product of the
magnetic moment and B0 (Equation 1.4).
=−

(1.4)

For a magnetic field along the z-axis and from Equation 1.2 and 1.3, this can be stated as;
=−

=−

ħ

(1.5)

Where the difference in energy between the equally spaced spin states is;
∆ =ħ

(1.6)

This corresponds to a frequency (υ0) of electromagnetic radiation that can be found as
follows;
Given; ∆ = ℎ
=

=ħ
(1.7)

For magnetic field strengths typical in MRI and NMR, these frequencies correspond to
the RF region of the electromagnetic spectrum.
The extent to which each state is populated is governed by the Boltzmann distribution
law (Equation 1.8) where Nα and Nβ are the number of protons in the low (anti parallel)
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and high (parallel) energy states respectively, kB is the Boltzmann distribution constant, T
is the absolute temperature and ∆E is the difference in energy between the two states.
∆"

ħ&$

= ! #$ % = ! #$ %

(1.8)

Due to energy considerations a slight excess of spins reside in the lower energy spin state.
From Equation 1.8 it can be seen that the spin populations are influenced by the strength
of B0 and temperature. For a typical magnetic field strength used in clinical MRI of 1.41
T and at a temperature of 37 °C, this population difference is approximately 1 spin per
100000 spins, i.e. ~10 ppm.
Two, B0 exerts torque on the individual magnetic moments of the proton nuclei and they
begin to precess out of phase with the angular momentum, I, at some constant angle
around the axis of B0. The angular frequency of this precession, which corresponds to the
energy difference between the two spin states as described above, is termed the Larmor
frequency (ω0) and is dependent on γ and the strength of B0 (Equation 1.9). Equation 1.9
describes the Larmor frequency for a proton with respect to the direction of precession
about B0, where the negative sign indicates a negative sense of precession (clockwise)
when viewed from a position above the direction of B0.
ω =−

(1.9)
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The end result of these two processes is that a net macroscopic magnetization (M), a
vector sum of all the individual spin magnetic moments, is induced. When viewed from
the rotating frame of reference (i.e. the x,y-axis is rotating at the Larmor frequency), M
lies directly along the z-axis, longitudinal to the direction of B0. Figure 1.1 summarizes
the influence of B0 on a collection of proton nuclei.

Figure 1.1: Summary of the influence of B0 on a collection of proton nuclei. a) Degenerate
nuclear spin orientations in the absence of B0. b) Non-degenerate nuclear spin orientations in
the presence of B0. c) Excess spins randomly precessing around B0. d) Net magnetization
longitudinal to the direction of B0 viewed from the rotating frame of reference.

1.2.2. Signal detection
In the above section a net magnetization vector (M) was established. This represents a
vector sum of the entire ensemble of spins, whose magnitude is determined by the
population difference (spin excess) between spin states. This difference in population, on
the order of parts per million (ppm), is the origin of the MRI signal. But, it is also the
source of the relatively poor sensitivity of MRI. Unfortunately the nuclear longitudinal
magnetization is practically undetectable as its signal is swamped by three orders of
magnitude of diamagnetism derived from the electrons (diamagnetic shielding).16
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In order to detect the net magnetization it must be rotated in to the x,y-plane, transverse
to the direction of B0. This is achieved by perturbation of the magnetization with a
second magnetic field (B1) that is weak, relative to B0, and generated by the application of
a RF pulse, typically along the x-axis. The result is that the magnetization is effectively
rotated away from B0 and the diamagnetism of electrons where it can be detected. In
order for this to occur, the frequency of B1 must match the Larmor frequency of the
magnetic moments causing the spins to resonate.

Under these conditions, the spins in

the lower energy state absorb the RF energy and are promoted to the higher energy state,
resulting in equalization of the spin populations. In addition, the B1 pulse causes the
individual magnetic moments to begin to precess together, i.e. in phase (phase coherent),
and for magnetization to grow in the x,y-plane (transverse magnetization). The extent of
the rotation of the magnetization is dependent on the strength and duration of the B1 field,
with maximum signal intensity being observed when the magnetization is rotated 90°.
The net magnetization precesses at the Larmor frequency (ω0) in the x,y-plane,
generating a rotating magnetic field and an associated electric field. This electric field
drives an oscillating electric current (the signal) in a wire coil near the sample in the x,yplane. Figure 1.2 summarizes the influence of a 90° B1 pulse on the net magnetization.
1.2.3. Longitudinal relaxation
After the pulse is turned off the gate to the RF receiver opens and a free induction decay
(FID) signal is detected and the spins relax back to thermal equilibrium. The thermal
equilibrium state is that in which the spin populations of the energy levels are those
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predicted by the Boltzmann distribution and one in which no coherences exist, i.e. no
component of the net magnetization is in the x,y-plane.

The return of the spin

populations back to those predicted by the Boltzmann distribution, where an excess of
spins are in the low energy spin state, requires dissipation of energy from the high energy
spin states. This occurs as a result of field fluctuations that arise primarily from magnetic
dipole-dipole interactions. This regenerates magnetization longitudinal to B0 along the z
axis and is termed longitudinal relaxation. Longitudinal relaxation is characterized by the
time constant T1, and the rate of the change of magnetization follows first order kinetics.

Figure 1.2: A summary of the influence of a 90° RF B1 pulse on the net magnetization. a) A 90°
RF pulse promotes spins from the low energy state to the high energy state. b) When the RF
pulse is complete the spin populations are equalized and precess in phase. The net
magnetization has rotated into the x,y-plane generating transverse magnetization.

Derivation of the general solution to the integrated first order rate law demonstrates that
the return of the magnetization to equilibrium from its position immediately after a RF
pulse is turned off, is exponential in form, Equation 1.10, where Mz(τ) is the
magnetization at a given delay time (τ), Mz(eq) is the equilibrium magnetization after
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complete recovery, Mz(0) is the magnetization at the time, τ = 0, directly after a RF pulse,
T1 is the longitudinal relaxation time constant and !

(

)
%

*+,! = -./ 0 − /

is the exponential decay function.
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Exponential recovery of the z component of the net magnetization towards equilibrium
along the z axis after a 90° RF pulse (Equation 1.11) can be derived by expressing
Equation 1.10 as:
/ 0 =/

12

−/

12

@1 −

C
/ 0
(
F! 5
/ 12

This simplifies to;
/ 0 =/

12

@1 − @1 −

C
/ 0
(
F! 5 F
/ 12
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For a 90° pulse Mz(0) is 0, and if we let Mz(eq) be 1, then this simplifies further to;

/ 0 = 1 @1 − @1 −
/ 0 =/

F!

12

I1 − 1 − 0 !

12

/ 0 =/

/
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12
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J
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J
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(1.11)

For a delay time (τ) equal to one time constant (T1) it can be shown that the
magnetization recovers 63% towards equilibrium (1) on the z axis.

/ 0 = 74 = 1 I1 − !

(

5
5

1
1
J = 1 I1 − J = 1 I1 −
J = 0.63 = 63%
!
2.718

T1 values are often determined using an inversion recovery pulse sequence. This pulse
sequence employs an initial 180° RF pulse that inverts the net magnetization to the –z
axis such that Mz(0) is equal to –Mz(eq), i.e. -1. Equation 1.11 can therefore be re-written
to describe the recovery of the net magnetization after a 180° RF pulse as;
/ 0 = 1 I1 − 2!

(

)
%

J

(1.12)
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After one T1, 63% of the magnetization will recover towards equilibrium on the +z axis
(+1). Since the initial magnetization is on the –z axis (-1), the magnetization after one T1

is 63% of 2 plus the initial magnetization (-1), i.e. 2 × (0.63) + -1 = 0.26, as shown;
/ 0 = 74 = 1 I1 − 2!

(

5
5

1
1
J = 1 I1 − 2 J = 1 I1 − 2
J = 0.26
!
2.718

The inversion recovery pulse sequence consists of a series of radiofrequency (RF) pulses

and time delays17 (Figure 1.3). An initial 180° RF pulse along the +x axis (B1(180)x) ①
inverts the net magnetization from its equilibrium position along the +z axis parallel to B0
to the –z axis ②. During the pulse delay (τ) the magnetization is allowed to relax back
towards equilibrium, after which a 90° RF pulse is employed along the +x axis (B1(90)x)
③ and converts the remaining magnetization into the x,y-plane where the FID signal is

detected ④. A relaxation delay time (RD) allows full relaxation of the magnetization

back to equilibrium to occur prior to the next iteration of the pulse sequence ① with a
longer pulse delay time (τ).

Figure 1.3: IR timing diagram (top), course and position of the net magnetization (bottom).
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1.2.4. Transverse relaxation
The loss of phase coherence of spins, transverse relaxation, occurs via fluctuating
magnetic fields caused by molecular motions and B0 field inhomogeneities. Transverse
relaxation is characterized by the time constant T2, the decay time constant for the loss of
magnetization in the x,y-plane and the return to its equilibrium value (0), and also follows
first order kinetics. Derivation of the solution to the integrated first order rate law
demonstrates that the loss of transverse magnetization is also exponential in form,
Equation 1.13, Mxy(τ) is the magnetization at a given delay time (τ), Mxy(0) is the
magnetization at time 0 directly after a RF pulse, T2 is the transverse relaxation time
constant and !

(

)
%

is the exponential function of the decay.
/XY 0 = /XY 0 !

(

)
%

(1.13)

After a 90° pulse Mxy(0) is 1. From Equation 1.13 it can be determined that for a delay
time (τ) equal to one time constant (T2), magnetization in the x,y-plane decays to 37% of
its original value (1);
/XY 0 = 7

= 1!

(

5
5

1
1
= 1I J = 1I
J = 0.37 = 37%
!
2.718

T2 can be determined from a CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence named
after the contributing scientists responsible for its development.

The CPMG pulse

sequence consists of a 90° excitation pulse followed by a 180° (π) pulse that refocuses
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de-phasing spins in the x,y-plane to produce an echo signal. However, to ensure time
constants more closely reflect the true T2 value rather than T2* which includes
contributions due to de-phasing that arises from the inhomogeneity of B0, a train of phase
encoded 180° pulses are employed. The alternating phase of each 180° pulse of the train
reduces the inherent errors associated with each pulse through averaging, thereby
improving the accuracy of T2 values.18 With respect to Figure 1.4, the CPMG pulse

sequence employs a 90° RF pulse (B1) ① that converts the net magnetization into the
x,y-plane ②. The FID here is ignored. Instead, during a pulse delay time (τ) the spins

begin to dephase, after which a 180° pulse is applied ③. The 180° pulse inverts the
ensemble of spins ④ and they begin to re-phase such that after another pulse delay time

(τ) the coherences are restored and an echo signal is detected for which the FID signal is
recorded ⑤. This is repeated for a train of 180° pulses of alternating phase along the yaxis where the exponential decrease of the echo signal intensity is due to the effective T2.
After the final echo of the train a relaxation delay time (RD) allows full relaxation back
to equilibrium prior to the next iteration of the pulse sequence ①.

Figure 1.4: CPMG timing diagram (top), course and position of the net magnetization (bottom).
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1.2.5. Fourier transformation, T1 and T2 determination
The macroscopic transverse magnetization components of the FID in the x,y-plane as a
function of time t, take the following forms;
/X = G/12 − / , H sin ], !

(

^
5

/Y = −./12 − / , 3 cos ], !

(

a
%

(1.14)

The analogue FID signal picked up by a receiver coil in the x,y-plane is digitized for
computer processing. Digitizing the FID produces a time domain function, s(t), where
each time point corresponds to signal amplitude. The digitized signal is complex, i.e.
comprises values from both the x and y components of the magnetization and is known as
quadrature detection. The FIDs recorded for all iterations of the pulse sequence with
varying pulse delay times (τ) are mathematically transformed to the frequency domain
S(ω), a function of the initial signal amplitude in the time domain, s(t).

This is

accomplished by a Fourier transformation (Equation 1.15) taking as the input both
components of the net transverse magnetization, Mx and My from Equation 1.14.
b ] = ∑f d , cos ], − e sin ],

(1.15)

T1 is determined by plotting the signal intensity (S) of the peak maximum in the
frequency domain at ④ (Figure 1.5, top) as a function of τ, the pulse delay time (Figure
1.5, bottom) and fitting to Equation 1.12
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t

ω

④
63% Mz(0)

1 x T1

Figure 1.5: Summary of T1 determination. IR pulse sequence and generation of spectra (top)
and the evolution of magnetization (Mz) as a function of the variable pulse delay time (τ) (bottom).

T2 is determined by plotting the signal intensity (S) of the peak maximum in the
frequency domain at ⑤ (Figure 1.6, top) as a function of τ, the pulse delay time (Figure
1.6, bottom) and fitting to Equation 1.13.
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Figure 1.6: Summary of T2 determination. CPMG pulse sequence and generation of spectra
(top) and the decay of magnetization (Mxy) as a function of the variable total pulse delay time (τ)
(bottom).

1.3. Inherent soft tissue contrast and image weighting
The molecular composition of human soft tissue can be broadly divided into either water
or macromolecules (lipids, carbohydrates, proteins etc). These molecules contain a vast
number of hydrogen atoms (about 67% of all atoms in tissue), the source of signal in
most MRI. By applying a gradient magnetic field on top of the static B0 field, each
hydrogen nuclei experiences a slightly different total magnetic field and resonate at
slightly different Larmor frequencies. This introduces spatial encoding allowing a three-
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dimensional image to be generated. The signal intensity within an imaging voxel (1
mm3) is reported as relative brightness thus producing contrast in the image. The signal
intensity is, in part, related to the number of hydrogen atoms in the voxel, proton density,
a biologically variable parameter, and, to tissue T1 and T2 time constants discussed above,
which also vary from tissue to tissue.
A spin echo (SE) pulse sequence19 is capable of extracting inherent proton density [H+],
T1 or T2 contrast. A traditional SE pulse sequence has the same features as a CPMG
pulse sequence but with a single echo generated by a single 180° refocusing pulse (Figure
1.7). With appropriate selection of the echo time (TE), the time between the initial 90°
RF pulse and the echo signal, and the repetition time (TR), the time between consecutive
90° RF pulses of subsequent scans, image contrast can be biased, or “weighted”, towards
any of the three contrast mechanisms discussed.

Figure 1.7: Spin echo pulse timing diagram for weighted imaging.

This can be seen from the signal intensity equation for this pulse sequence (Equation
1.16) where; S is the amplitude of the signal in the frequency domain, k is a constant that
depends on the signal detection sensitivity of the instrument being used, [H+] is the
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proton concentration and T1 and T2 are the longitudinal and transverse relaxation time
constants respectively. It is apparent from this equation that TR is related to T1 and TE to
T2, and that [H+] is unrelated to either T1 or T2 but is always present to some extent.
b = - g h I1 − !

(

%i
∙
%

!

(

%"
%

J

(1.16)

If TR is set to be longer than T1 then the term e-TR/T1 tends to 0 and T1 effects on image
contrast will be suppressed. This is a result of negligible differences in signal intensity
between two tissues with different T1 values as magnetization recovers towards
equilibrium. Likewise, if TE is set to be shorter than T2 then the term e-TE/T2 tends to 1
and T2 effects on image contrast will be suppressed. In this situation, little decay of the
signal has occurred and again there is a negligible difference in signal intensity between
two tissues with different T2 values. If a SE pulse sequence is employed in which both T1
and T2 effects are suppressed (short TE and long TR) then image contrast will be
weighted towards the remaining contribution, proton density, where greater numbers of
protons in a voxel generates increased signal intensity. In practice, all images generated
with the SE pulse sequence contain a mix of each contrast mechanism. Experimentation
and experience is required to optimize the desired contrast between tissues of interest. A
summary of the effects of different types of image weighting on brain tissue contrast
between ventricles, that contains CSF (cerebrospinal fluid), an aqueous fluid, and white
matter, that consists of a large amount of lipid containing myelin, is shown in Figure 1.8.
T1 and T2 time constants for CSF and white matter were obtained from literature at 1.5
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Images were generated with the specified parameters using a web-based

simulation21 with consent from the creator.
CSF contains mostly water, a fast tumbling small molecule for which the frequency of
the oscillations of the proton magnetic dipole is typically greater than the Larmor
frequency. This results in inefficient dipole-dipole interactions due to short correlation
times (τc), the time two dipoles spend interacting, and thus long time constants. Water
molecules associated with macromolecules in soft tissue such as white matter and protons
that are part of the macromolecular structure are less free to rotate.

As such, the

oscillation of the proton magnetic dipole is closer to the Larmor frequency leading to
longer correlation times and shorter time constants. If TR is long, >> T1, and TE is short,
<< T2, then the resultant image is proton density-weighted as both T1 and T2 effects are
suppressed (Figure 1.8, top row). In this case the proton density-weighted image is
essentially isointense with little contrast between the bright internal volume of the
ventricles and white matter. This is a result of high proton densities in the two tissues,
the ventricles, which contains CSF (cerebrospinal fluid), a water based fluid, and white
matter which consists of large amounts lipid containing myelin. If TR is long, >> T1, and
TE is approximately the average of the expected T2 values of the tissues for which
contrast is desired, then the image is T2-weighted, with T1 effects being suppressed
(Figure 1.8, middle row).

In a T2-weighted image the CSF in the ventricles is

hyperintense as a result of its longer T2 value compared to white matter, which appears
hypointense. Conversely, If TE is appropriately selected in order to suppress T2 contrast,
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typically < T2, and TR is approximately the average of the expected T1 values of the
tissues for which contrast is desired, then the image is T1-weighted (Figure 1.8, bottom
row). In a T1-weighted image the CSF in the ventricles is hypointense as a result of its
longer T1 value compared to white matter, which appears hyperintense.

Figure 1.8: Effect of image weighting on contrast between CSF in the ventricles and white
matter. Proton density-weighted (top), T2-weighted (middle) and T1-weighted (bottom).
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1.4. Gd3+-based contrast agents for soft tissue contrast enhancement
Contrast generated by T1-weighting can be enhanced by the intravenous administration of
an extracellular Gd3+-based contrast agent (CAs). In 2007, 43% of the 27 million scans
performed in the US required contrast enhancement from such agents.8 Their ability to
increase contrast between tissue in which they are taken up (typically diseased) and
neighboring tissue (typically healthy) has been the subject of much research22-29 by
chemists since the early 1980’s when they were first introduced.30 This has led to
unparalleled improvements in tissue discrimination by increasing water proton relaxation
rate constants of tissue in which they are taken up relative to surrounding tissue that
would otherwise be in a similar magnetic environment and generate little contrast.
Contrast agents are particularly useful for the imaging of brain pathology. In healthy
brain tissue an intact blood brain barrier (BBB) prevents a contrast agent from entering
cells. However, in diseased tissue the BBB can become damaged allowing a contrast
agent to enter. In this case, contrast agents can be thought of as a means of identify the
disruption of the BBB, particularly useful for pathologies such as multiple sclerosis.
1.4.1. Classification of clinically approved Gd3+-based CA
Over the last 25 years or so several Gd3+-based CAs have been approved for clinical use
in the US and EU and fall into one of three classes based on their biodistribution (Figure
1.9). All are extra cellular agents, with those that are excreted exclusively through the
kidneys belonging to one class and those that exhibit some biliary clearance belonging to
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another. Those restricted to the intravascular compartment due to binding and their
increased size make up a third class.

Figure 1.9: Distribution and excretion pathways for clinically approved Gd3+-based CAs.

Six of the nine FDA approved agents are very hydrophilic do not exhibit any specific
binding properties (Figure 1.10). After intravenous injection they circulate in the
extracellular fluid compartment (ECF) prior to elimination through the kidneys. Chelates
of Gd3+ in which the diethylenetriaminepentacetate (DTPA) ligand scaffold is modified
to contain a benzyl substituent (Figure 1.11) are taken up by hepatocytes31 and cleared, to
a degree (2 – 4%), via the hepatobiliary system making them useful for liver imaging
application. The relaxivity of these agents are elevated compared to the ECF agents due
to a slight binding function (~10%) between the benzyl group and plasma proteins.32 The
third class of clinically approved Gd3+-based CAs contains just one agent, Ablavar,
(Figure 1.12). Expanding on the success of MulitHance and Eovist/Primovist, Ablavar
allows for an even greater increase in relaxivity to be observed via a reversible binding
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function with serum albumin that lengthens the rotational correlation time due to the
large effective molecular weight.

Ablavar contains a lipophilic biphenylcyclohexyl

group for binding and restricts access to the interstitial compartment making it
particularly useful for the imaging of the blood pool. The binding moiety is attached to a
pendant arm of the DTPA ligand via a phosphodiester linker that results in Ablavar being
eliminated renally.

Figure 1.10: Class 1: Extracellular fluid (ECF) agents.
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Figure 1.11: Class 2: Extracellular fluid (ECF) and liver agents.

Figure 1.12: Class 3: Blood pool agent with serum albumin binding moiety.

These agents can be further categorized as being derived from macrocyclic (category A)
or linear (category B) parent ligands (Figure 1.13) or bulky chelates (category C) (Table
1.1).
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Figure 1.13: Macrocyclic and linear parent ligands for clinical Gd3+-based CAs.

Table 1.1: Physical properties of the three categories of Gd3+-based CAs studied.
a

Obtained from Weinmann et al.33

b

Observed equilibrium relaxivity with human serum albumin

(HSA) bound and free contributions. All other data readily obtainable from supplier information.

1.4.2. Stabilization of Gd3+-based CAs
Free Gd3+ is both insoluble at physiological pH and is known to be toxic.34 Toxicity
arises due to the ability of Gd3+ to take part in transmetallation with other important
biological cations such as Ca2+, Cu2+ and Zn2+, thus disrupting important cellular
mechanisms,35 a factor worsened by its long residence time in the body and evidence
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showing deposits in skin and bone.36-41 Therefore, Gd3+-based CAs must be formulated
with the metal ion bound extremely tightly to an organic ligand.

This affords

thermodynamically and kinetically stable nontoxic chelates which are cleared more
rapidly than they dissociate, such as those in clinical use shown above in Figures 1.10 –
1.12.
1.4.3. Mechanism of action of Gd3+-based CAs
Gd3+-based CAs can be rationally designed for optimum per molar effectiveness
(relaxivity) and for targeting specific tissue type to allow for more localized contrast
improvement and improved clinical relevance and has been extensively published and
reviewed22-29 The basic pre-requisite of a CA for MRI is that it should increase the
relaxation rate constant of bulk water protons. To that end, almost any paramagnetic
solute could be used since relaxation processes occur as a consequence of the interactions
between magnetic moments of unpaired electrons and those of interacting nuclei.
However, the trivalent paramagnetic gadolinium ion (Gd3+) has garnered most attention.
This is due to its seven unpaired f electrons (maximum available) and long electron
relaxation times (τS) that allow for increased efficacy of relaxation of the interacting
water proton nuclei.22 In the presence of a Gd3+ ‘bound’ water molecule, these properties
lead to shorter longitudinal relaxation time constants for the bound water protons (T1M)
which, when in fast exchange with bulk water, are able to transmit the paramagnetic
relaxation enhancement (PRE) effect more effectively and thus increasing their relaxivity
(r1), described as the paramagnetic relaxation enhancement (R1observed - R1w) normalized to
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the Gadolinium concentration (Equation 1.17). Where; R1observed is the observed tissue
water proton longitudinal relaxation rate constant (the inverse time constant) and R1w is
the longitudinal relaxation rate constant of pure water (or other solvent).
*4 =

k lmnDopDq (k r
st

(1.17)

1.4.4. Contributions to the PRE effect
The observed longitudinal relaxation rate constant (R1obs) of water protons in the presence
of a Gd3+-based CA has several contributions as a consequence of various spheres of
water molecules surrounding the metal ion, each of which are in a constant and rapid
exchange with the bulk water protons and contribute to the paramagnetic relaxation
enhancement to different extents (Equation 1.18).

R1Inner-sphere is the inner sphere

relaxation rate constant, R1Second-sphere is the second sphere relaxation rate constant, R1Outersphere

is the outer sphere relaxation rate constant and R1w is the solvent relaxation rate

constant. Figure 1.14 shows a cartoon representation of the several spheres of water
surrounding a typical Gd3+-based CA.
u4vwx1yz1t = u4{{1y(x|}1y1 + u4~1•€{t(x|}1y1 + u4v•^1y(x|}1y1 + u4‚

(1.18)

The coordination number of the Gd3+ ion ranges from eight to ten; however, it is typically
nine as in the case of each of the chelates approved for clinical use. Eight are occupied
by the organic chelating ligand and one by a single water molecule, the inner sphere
water, which defines the hydration number (q) of the complex.
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Figure 1.14: Schematic of the spheres of water that contribute to relaxivity of Gd3+-based CA.

A chelates inner sphere contribution (R1IS) to R1obs is well described by SolomonBloembergen-Morgan (SBM) theory42-45 and has been shown to be dependent on the
hydration number, the inner sphere water proton relaxation time constant (T1M), the water
proton residence life time (τM) and the molar concentration of Gd3+ (c) (Equation 1.19).
u4~ = ƒƒ.„ G5 †
•×2

4

… hC…

H

(1.19)

Second sphere contributions (R1SS) to R1obs occur due to an ordered sphere of water
molecules beyond the inner sphere water molecules. Second sphere water molecules are
in close proximity to the metal ion and are also well described by SBM theory and the
parameters outline above for R1IS. Second sphere contributions have been shown to arise
as a result of hydrogen bonding between the second sphere water molecules and lone
pairs on the ligand groups.28 Outer sphere contributions (R1OS) to R1obs occur due to
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diffusion of the complex through the water and can be described by modified Freeds
equations.46
1.5. Traditional methods for optimization of relaxivity: A discussion of SBM theory
1.5.1. Motives for increasing relaxivity
Relaxivity has long since been established by SBM theory to be magnetic field
dependant.42-45 This dependence can be determined using a field cycling relaxometer
developed from the technical concepts of Anderson and Redfield.47 The instrument is
able to rapidly measure relaxivity as a function of a large range of magnetic field
strengths. A plot of such measurements is known as a nuclear magnetic relaxation
dispersion (NMRD) profile. The NMRD profile for Dotarem, the original cyclic Gd3+based CA approved for clinical use, is shown in Figure 1.15 (dashed line). As can be
seen the relaxivities are significantly reduced at current clinical imaging fields of 1.41 – 3
T (60 – 128 MHz) and continue to decrease as field strength increases further, a
considerable concern given the current trend towards greater magnetic field strengths14
that afford improved signal to noise.15
Since inherent tissue T1 increases with increasing B0,48 agent detectability is improved.
However, these gains are not fully realized due to the decrease in relaxivity at higher B0
fields. This results in Gd3+-based CAs having high detection limits, a problem faced by
chemists since their introduction into diagnostic radiology in the early 1980s,49 and
necessitates high doses be administered. High doses cause a significant reduction of the
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tissue T1 and leads to an observable change in image contrast, determined from the
change in T1 in the presence of the agent with respect to the inherent T1 of the tissue.

Figure 1.15: The nuclear magnetic relaxation dispersion (NMRD) profile of Dotarem (dashed
line50) plotting laboratory frame relaxivity as a function of B0 field, the outer-sphere contribution is
shown by the dotted line. Also plotted is the NMRD profile of a theoretically “optimized”
gadoterate chelate (solid line).

Despite of these significant shortcomings, tissue contrast in MRI is remarkable and
spatial resolution unsurpassed. The driving force behind the quest for higher relaxivities
comes from the desire to perform molecular imaging which entails selectively targeting
CAs to biomarkers of disease pathology that exist in very low concentrations. Assuming
1:1 binding stoichiometry between target and agent it can be calculated that for current
agents that have a relaxivity between 4 and 5 mM-1 s-1, the target molecule must be
present at ~125 µM or greater51, a value that limits the number of target candidates.
Contrast agents with lower detection limits as a result of their high relaxivity will make
this more feasible and shows the importance of optimizing agent relaxivities.
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1.5.2. SBM parameters for optimizing relaxivity
Researchers have given most attention to optimizing agent relaxivity through
modifications to the inner sphere contribution (R1IS) to the observed longitudinal
relaxation rate constant; the outer sphere contributions are fixed by limitations of realistic
contrast agent design. From Equation 1.19 it can be seen that a limited number of
parameters are available to affect R1IS. These are; the hydration number of the Gd3+ ion,
the inner sphere water proton relaxation time constant (T1M) and the lifetime of an inner
sphere coordinated water molecule, τM.
1.5.3. Hydration state (q)
All clinical Gd3+-based CAs have one metal bound water molecule and therefore are q =
1 agents. Opening up additional coordination sites to water by reducing the denticity of
the ligand can lead to increases in relaxivity. However, this is often at the expense of
increased agent toxicity, a result of decreased selectivity of the ligand for Gd3+ versus
endogenous metals rather than directly related to stability.52

In addition to their

decreased stability, agents with reduced ligand denticity are more prone to binding
endogenous anions, such as phosphate, that displaces the inner sphere water leading to
decreased relaxivities.53 Reports have recently been made of chelates in which q = 2.54-55
However, it is unclear that these chelates would be sufficiently stable for human use.
Therefore, the hydration state is essentially fixed at one.

CHAPTER 1. Introduction

35

1.5.4. Inner sphere water proton relaxation time constant (T1M)
To understand the factors that influence the inner sphere water proton relaxation time
constant (T1M) further analysis of SBM theory is required. T1M has been found to be
highly dependent on the longitudinal (τc1) and transverse (τc2) correlation time constants,
and on rGd-H-6, the distance between the metal ion and the coordinated water proton
(Equation 1.20). The latter is comparable for all clinical q = 1 agents and has historically
been considered to be fixed. All other components in Equation 1.20 are constants where;
µ0 is the permeability of free space, ħ is the reduced Plancks constant equal to h/2π, γH
and γS are the gyromagnetic ratios of a proton and electron respectively, S is the electron
spin quantum number, ωH and ωS are the proton and electronic Larmor frequencies
respectively.
4
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τc1 and τc2 are themselves dependent on the rotational correlation time constant (τR), the
water residence life time (τM) and the longitudinal and transverse electron relaxation time
constants (τS1 and τS2 respectively) as shown in Equation 1.21. Control of the later is less
well understood and values for a given chelate have to be accepted.
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Using these equations and fixing values for c, q, rGd-H and τS, the effect of τR and τM on
relaxivity can be modeled. Such models show τR and τM values are key parameters for
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relaxivity enhancement. A relaxivity plot as a function of these two critical parameters at
a fixed field strengths is often published. Figure 1.16 is typical of such plots and
demonstrates the effect of τR and τM for a generic Gd3+ chelate at 0.47 T (20 MHz).

Figure 1.16: 3D simulation illustrating the effect of the rotational correlation time (τR) and the
residence lifetime of the water molecule (τM) coordinated to a metal ion for a generic Gd3+ chelate
at 0.47 T (20 MHz).

1.5.5. Rotational correlation time constant (τR)
Bulky agents restrict the ability of the molecule to tumble in space resulting in lengthened
τR values. This has a favorable outcome in terms of relaxivity gains but their increased
size also restricts movement from the vasculature to the interstitial space. τR is optimized
when the rotational frequency is comparable to the proton larmor frequency at the
imaging field strength. Most clinical imaging is performed at 1.41 – 3 T (60 – 128 MHz)
therefore the GHz τR values for clinically available q = 1 low molecular weight agents56
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are too fast, requiring their rotation to be slowed to become more optimum, such as in the
case of Ablavar (Figure 1.12).
Ablavar consists of a stable gadopentate core, with a phosphodiester linkage to a
lipophilic albumin binding group. On binding (non-covalently) to human serum albumin
(HSA) the effective molecular weight increases substantially and thus τR increases
resulting in an increase in relaxivity. Several derivatives of this type of CA have been
investigated including variants covalently bound to large macro and supramolecular
carriers.57
1.5.6. Water residence life time (τM)
The time a water molecule spends associated with the Gd3+ ion is its water residence
lifetime (τM). The inverse of which describes the exchange kinetics of the inner sphere
water molecules. If the water molecule is coordinated for too short a time before being
exchanged with a bulk water molecule, and catalyze the PRE effect, then the water proton
will not be fully relaxed and optimum relaxivity will take longer to reach. Conversely, if
the water molecule remains associated fully relaxed for too long before being transferred
to the bulk (as is the case for clinical Gd3+-based CA) then the efficiency of the relaxation
is poor and relaxivity is not optimum. Investigations reveal that the optimum value of τM
for clinical agents is approximately 6 ns at the clinically relevant field strength of 1.41 T
(60 MHz)58 compared to about 20 – 40 ns at 0.47 T (20 MHz).
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1.5.7. Electron relaxation time constants (τS1 and τS2)
Although the effect of electron spin relaxation time constants, τS1 and τS2, on relaxivity is
known59-60 and can be predicted by SBM theory, methods to accurately control their
values are less well understood.

According to experimental observations, increased

rigidity and symmetry within a chelate, such as those based on the cyclic ligand DOTA,
gives rise to better electron relaxation than with chelates based on the linear ligand
DTPA, particularly for complexes that tumble slowly.22, 61 This latter point makes them
field dependent parameters as a result of the dependence of τS1 and τS2 on the zero-field
splitting (ZFS) and is characterized by the correlation time (τυ) expressed by the square of
the trace of the ZFS tensor, ∆ , as shown in Equations 1.22 and 1.23 respectively. All
other terms are constants as described previously.
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1.6. Spin locking for recovering lost relaxivity
In spite of the relatively sound understanding of all that has been discussed above,
relaxivities of Gd3+-based CAs at clinical imaging fields are significantly lower than
predicted by theory (Figure 1.15). Moreover, these values are much reduced from those
obtainable at lower fields and continue to decrease as field strength increases. Therefore,
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a method to “recover” lost relaxivity from current clinically approved agents at high field
strengths that retain SNR advantages could be adopted into clinical practice rapidly and
would be of tremendous importance.
1.6.1. Theory of spin locking
The technique was initially investigated as an NMR technique in the 1950’s,62 but
developed for imaging 30 years later63 where it has been used extensively in nonenhancing tissue since.64-69 Spin locking refers to the application of a lower power,
longer duration RF pulse (B1) in the x,y-plane phase shifted from a 90° B1 excitation
pulse such that it is parallel to the net magnetization. The purpose of which is to “lock”
the magnetization into lower precessional frequencies around an “effective” field (Beff)
that is reduced with respect to B0 but maintains the high field advantages required for
imaging. When considered in the rotating frame of reference, longitudinal relaxation of
the magnetization against Beff exhibits time constants (T1ρ) representative of those at the
lower precessional frequencies induced by the spin locking pulse and this has
implications for increasing CA detectability.
1.6.2. Determination of rotating frame longitudinal relaxation time constants (T1ρ)

T1ρ values are determined using a spin lock pulse sequence (Figure 1.17). An initial 90°
RF excitation pulse along the +x axis (B1(90)x) ① converts the net magnetization into the

x,y-plane ②. Directly after which, the B1(90)x is turned off and a lower power, long
duration 90° spin lock RF pulse phase shifted by 90° (B1(90)y) is turned on for a period of
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time (τ) known as the locking time (TL) and generates an effective field (Beff).
Throughout the duration of the spin lock pulse the net magnetization is locked in the x,yplane and undergoes longitudinal relaxation in the absence of transverse relaxation.
When the spin locking pulse is turned off the signal from transverse magnetization in the
x,y-plane is detected ③. A relaxation delay time (RD) allows full relaxation of the

magnetization back to equilibrium to occur prior to the next iteration of the pulse
sequence ① with a longer locking time (τ).

Figure 1.17: Spin lock pulse timing diagram (top), course and position of the net magnetization
(bottom).

T1ρ, the longitudinal relaxation time constant in the rotating frame measured as the decay
of transverse magnetization, is determined by plotting the signal intensity (S) of the peak
maximum in the frequency domain at ③ (Figure 1.18, top) as a function of τ, the spin
locking time (Figure 1.18, bottom). As for T2, T1ρ is the time required for magnetization
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in the x,y-plane to decay to 37% of its original value (1) and is calculated by fitting the
acquired data to Equation 1.24 that describes the decay of magnetization from the x,yplane after a 90° phase shifted SL pulse and !

(

)
% –

/XY 0 = /XY 0 !

t

(

is the exponential decay function.

)
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ω

③

37% Mxy(0)

1 x T1ρ
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Figure 1.18: Summary of T1ρ determination. Spin locking pulse sequence and generation of
spectra (top) and the decay of magnetization (Mxy) as a function of the variable spin lock duration
(τ) (bottom).
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1.7. Scope of this work: Determining the effect of a spin locking pulse on relaxivity
The scope of this work is to determine the extent to which a spin locking pulse can
“recover” lost relaxivity over a range of relatively high B0 fields for a range of MRI
contrast agents.
1.7.1. Effect of pulse sequence parameters on T1 and T1ρ time constants
To compare relaxivities across several B0 field strengths it is essential that relaxation time
constants be obtained with parameters that offer the best possible fit of the data in order
to generate reliable NMRD profiles.

A number of pulse sequence parameters are

available that potentially alter the reliability of a fit to observed relaxation data.
Therefore, it was prudent to investigate the impact of deliberate variations to several
pulse sequence parameters on the fitting of laboratory and rotating frames relaxation data
and the subsequent time constants generated.
1.7.2. Effect of spin lock pulse strength (γB1) on longitudinal relaxation rate constants
(R1ρ)
Of the few reports relating to the rotating frame relaxation mechanism in the presence of
paramagnetic ions, the work by Jordan and co-workers70 stands out. In it they describe
the effect a hydrated paramagnetic ion would have on R1ρ of bulk solvent nuclei.
However, this paper did not investigate the effect of combining spin locking with
paramagnetic Gd3+-based CAs. Unique to Gd3+ of the lanthanide metal ion series, Gd3+
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2 ). This invokes a condition identified by the
does not induce a hyperfine shift (∆ωm

authors that suggests there should be no significant change in R1ρ as a function of the
strength of the spin locking pulse (γB1). A study to investigate this hypothesis is critical
in order to generate accurate r1ρ NMRD profiles for Gd3+-based CAs in which reliable
comparison of data across several fields and instrument types can be made.
1.7.3. A comparison of laboratory (r1) and rotating (r1ρ) frame longitudinal relaxivities
for q = 1 clinical Gd3+-based CAs
The use of a low field spin locking pulse in the presence of a large B0 field may allow for
the generation of relaxivities in the rotating frame for current clinically available Gd3+based CAs higher than is presently obtainable in the laboratory frame. This has potential
implications in any imaging applications that may require the administration of one of
several Gd3+-based CAs clinically approved for MRI. Therefore a study to determine the
extent of any increase in relaxivity by employing a spin locking pulse is critical to
provide greater detail of the potential to improve agent detectability.
1.7.4. Effect of rotational correlation time (τR) on rotating frame longitudinal relaxivity
(r1ρ)

It is also possible from the theory derived by Jordan et al. to hypothesize that r1ρ should
be more sensitive to the rotational correlation time (τR) than r1. This is due to the
introduction of the laboratory frame transverse relaxation rate constant (R2M) into the
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description of r1ρ and its dominance over the laboratory frame longitudinal relaxation rate
constant (R1M). Nanoassembled capsules (NACs) prepared by Annah Farashishiko in our
group that contain a q = 0 chelate (GdDOTP5-) bound to polymer and encapsulated in
SiO2 are a useful model for studying the effect slowly tumbling agents with long τR
values have on rotating frame relaxivities. A study to investigate the effect of spin
locking on the rotating frame relaxivities of NACs was performed and results compared
to the laboratory frame relaxivities over a range of B0 fields.
1.7.5. Effect of hydration number (q) on rotating frame longitudinal relaxivity (r1ρ)
It is well established that the laboratory frame longitudinal relaxivity (r1) of Gd3+-based
CAs scales with hydration number (q) at the expense of the thermodynamic stability of
the chelate. On opening up an extra coordination site to water, stability reduces by up to
as much as three orders of magnitude limiting the choice of agents for practical in vivo
use to those with a hydration number of just one.71 However, for ex vivo and post
mortem investigations stability of the CA is not a concern. Applications such as these
were just the reason we needed, other than for fundamental purposes, to study the effect
hydration number has on the rotating frame longitudinal relaxivity (r1ρ).
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EFFECT

OF

PULSE

SEQUENCE

PARAMETERS

ON

LONGITUDINAL (T1) AND ROTATING (T1ρρ) FRAME TIME CONSTANTS
2.1. Establishing pertinent pulse sequence parameters with potential to effect reliability
of fit of relaxation data
To compare relaxivities across several B0 field strengths it is essential that relaxation time
constants be obtained with parameters that offer the best possible fit of the data in order
to generate reliable NMRD profiles.

A number of pulse sequence parameters are

available that potentially alter the reliability of a fit to observed relaxation data. Herein,
we investigate the effect deliberate variations to pertinent pulse sequence parameters
have on the fitting of observed time curve data and the T1 and T1ρ values generated. For
this experiment, a PBS solution of Dotarem with a Gd3+ concentration of 25 mM was
used and single point (n = 1) measurements taken. For each parameter and temperature
investigated, the observed variance (standard deviation) in the time constants generated
over the range of deliberate variations were compared to the natural variance (standard
deviation) for a sample prepared in the same manner. The natural standard deviation was
determined from replicate analysis (n = 20) on the same sample using a fixed set of
parameter values. We limited the investigation to our 60 MHz (1.41 T) fixed low field
relaxometer to reflect current clinical imaging field strengths. Measurements were made
at historically and physiologically relevant temperatures, 25 and 37 °C respectively.
Time constants generated from time curves at 25 and 37 °C are presented and discussed
below. For clarity, a discussion of time curve fitting was restrained to time curves
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generated at 25 °C, however, comparable fitting and trends were observed for time curves
generated at 37 °C and can be found in appendix 1.
The pulse sequence parameters investigated were:
2.1.1. Relaxation delay (RD) time
The relaxation delay (RD) time defines the time between the detection of a signal and the
subsequent RF pulse of the next scan or iteration of the pulse sequence and should allow
sufficient time for full relaxation of the magnetization back to equilibrium to occur.
2.1.2. Pulse delay (τ) times
The pulse delay time defines the time magnetization is allowed to recover back to thermal
equilibrium against B0 and Beff for T1 and T1ρ measurements respectively prior to signal
being detected. For T1ρ measurements, this occurs in the presence of a spin lock pulse
and is called the spin lock time (TL). The pulse delays should allow for a full range of
signal intensities to be detected.
2.1.3. Number of data points
The number of data points (or pulse delays) dispersed across the range of pulse delays
sampled determines how closely spaced in time the pulse delays are. The number should
be appropriate for the type of exponential behavior expected and reduce instrument and
operator time.
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2.2. Establishment of ideal pulse sequence parameter values
The following table identifies the suggested “ideal” values for the pulse sequence
parameters to be investigated obtained from either the user manual72 or reported in
literature.73
Table 2.1: Suggested “ideal” pulse sequence parameter values for determinations of T1 and T1ρ.
Pulse sequence
parameter

Inversion
recovery

Spin locking

Relaxation delay time (s)

= 10 × T1

= 10 × T1
or minimum allowable ≥ 10 × T1

First pulse delay

< 1/10th × T1

< 1/10th × T1

Last pulse delay

> 5 × T1

> 5 × T1
or maximum allowed (40 ms)

16

16

Pulse delays times (ms)

Number of pulse delays for
mono-exponential behavior

2.3. Other parameters and general considerations
Several other parameters that a user would not typically alter but do affect the reliability
of fit of relaxation data if not controlled are discussed below for completeness. These
parameters were held constant for all experiments herein with the values stated where
applicable.
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2.3.1. Sample temperature, volume and position
Relaxation time constants are temperature dependent, therefore, the sample was inserted
into the coil of the probe head and equilibrated to the desired temperature for at least five
minutes prior to any measurements being made. To maximize the signal-to-noise a
sample volume sufficient to fill the RF receiver coil is recommended by the instrument
manufacturer. A volume of 0.5 mL was employed. The sample was positioned safely
within the built-in sample holder and the minispec operated on a benchtop that minimizes
vibrations and reduces pulse angle errors.
2.3.2. Pulse angles
The angle by which the net magnetization is flipped is determined by the power and
duration of the pulse. Pulse angles can be calibrated to ensure accurate flip angles are
achieved. For these experiments, 90° and 180° pulse angles were achieved with pulse
durations of 2.54 and 4.78 µs for 0 decibels attenuation. These values are provided by
the minispec software. however, at the time of writing are thought to be wrong.
2.3.3. Offset frequency
The offset resonance frequency should be equal to the resonance (Larmor) frequency of
the water protons determined by the spectrometer, i.e. on-resonance.
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2.3.4. Number of scans
The number of scans for all experiments was 4, 1 scan per phase, the minimum required
when the phase cycling option is selected.
2.3.5. Receiver gain, detection mode and fitting equations
Receiver gain was set to the factory installed setting (-66 dB). For T1 determinations the
“Real” detection mode was used. For T1ρ determination the “Magnitude” detection mode
was used to allow the full range of signal to be observed. A mono-exponential behavior
was expected, therefore, fitting to the relevant exponential equation (Equation 1.12 and
1.24) was satisfactory.
2.4. Determination of natural variance (standard deviation) from replicate analysis
Using the suggested “ideal” pulse sequence parameter values in Table 2.1 replicate (n =
20) determinations of T1 and T1ρ were made on a single sample preparation of Dotarem in
PBS pH 7.4 at a Gd3+ concentration of 25 mM. The time constants and the natural
variance in the data (measured as standard deviation) for each time constant at both 25
and 37 °C are presented (Table 2.2). Figure 2.1 shows more clearly the measurement
repeatability of the data. The difference due to temperature is a consequence of Dotarem,
a small molecule, being in the fast exchange regime and having a short correlation time
(τc). In this case, a decrease in temperature results in a decrease in the time constant due
to a lengthening of the correlation time and more efficient dipole-dipole interactions.
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Figure 2.1: Determination of natural variance in T1 and T1ρ at 1.41 T (60 MHz) for a single
sample preparation of Dotarem in PBS pH 7.4 with a Gd3+ concentration of 25 mM. The “ideal”
pulse sequence parameters identified in Table 2.1 were used.

It can be seen from the data presented in Figure 2.1 and Table 2.2 that the natural
variance in the repeatability data of T1 and T1ρ at both 25 and 37 °C is very low with
standard deviations of 0.10 and 0.067 ms for T1 measurements at 25 and 37 °C
respectively and 0.042 and 0.047 ms for T1ρ measurements at 25 and 37 °C respectively.
The standard deviations for time constants obtained by changing pulse sequence
parameter values shall be determined and compared to the standard deviations reported
above, where the above represents the natural variance from replicate analysis. If the
standard deviation for a series of time constants is greater than the standard deviation due
to natural variation in the data then the variation in the time constant values will be
considered significant and a result of the change to the parameter value. From this it will
be possible to make recommendations to ensure reliable time constants.
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Table 2.2: Determination of natural variance in T1 and T1ρ at 1.41 T (60 MHz) for a single sample
preparation of Dotarem in PBS pH 7.4 with a Gd3+ concentration of 25 mM. The “ideal” pulse
sequence parameters identified in Table 2.1 were used. SD is the standard deviation.
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2.5. Effect of pulse sequence parameters on the reliability of fit of relaxation data
2.5.1. Relaxation delay (RD) time
With the inversion recovery pulse sequence it was noticed that with a relaxation delay
time < 10 × T1 the measured signal for short pulse delay times (τ) are offset by ~20%
(Figure 2.2, squares) compared to when the relaxation delay is = 10 × T1 (diamonds), >
10 × T1 (triangles) or >> 10 × T1 (crosses). This demonstrates that a relaxation delay time
that is too short does not allow full relaxation back to equilibrium thus reducing the
signal of the subsequent scan.
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Figure 2.2: Effect of delibarate variations to the relaxation delay (RD) time on T1 time curves
(inset shows deviation (squares) when relaxation delay is < 10 x T1). Sample: PBS pH 7.4
solution of Dotarem, [Gd3+] = 25 mM. n = 1.
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With the spin locking pulse sequence almost identical time curves were generated (Figure
2.3) for all four RD times studied. This is due to the RD times employed all being >> 10
× T1 due to a 4 s minimum imposed by the instrument to preserve hardware during the
use of long pulse delays required to observe full signal decay.
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Figure 2.3: Effect of delibarate variations to the relaxation delay (RD) time on T1ρ time curves.
Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.

The measured standard deviation for time constants generated here (n = 1) from monoexponential fitting of the time curves are 0.015 and 0.00 ms for T1 measurements at 25
and 37 °C respectively and 0.031 and 0.050 ms for T1ρ measurements at 25 and 37 °C
respectively (Table 2.3). All standard deviations are approximately equal or less than the
natural variance (standard deviation) of the data. It can therefore be said that there was
no significant effect on time constants by varying the relaxation delay time.
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Table 2.3: Effect of deliberate variations to the relaxation delay (RD) time on T1 and T1ρ values at
1.41 T (60 MHz). Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. (n = 1).
T1 (ms)

T1ρ (ms)

RD time (s)

25 °C

37 °C

RD time (s)

25 °C

37 °C

0.01 (<10 × T1)

9.35

11.4

4 (>>10 × T1)

8.05

10.4

0.1 (=10 × T1)

9.32

11.4

8 (>>10 × T1)

8.09

10.3

1 (>10 × T1)

9.32

11.4

12 (>>10 × T1)

8.11

10.3

4 (>>10 × T1)

9.32

11.4

16 (>>10 × T1)

8.12

10.3

RD variance
(SD)

0.015

0.00

0.031

0.050

Natural variance
(SD)

0.10

0.067

0.042

0.047

2.5.2. Pulse delay (τ) times
By increasing the duration of the first pulse delay time (Figure 2.4) in the inversion
recovery and spin lock pulse sequences a smaller proportion of the relaxation time curve
is observed. This is due to relaxation occurring at a rate relatively fast compared to the
timing of the first pulse delay time. With a first pulse delay time of 0.01 ms (<< 1/10th ×
T1) and 0.2 ms (< 1/10th × T1) for the determination of T1ρ the measured signal for short
pulse delay times (τ) are scattered (Figure 2.4d and 2.4e). This is the result of small
coherences that remain in the transverse plane that are unable to relax during very short
delay times resulting in errors of the time constant estimation. On increasing the duration
of the first pulse delay time to 1 ms (= 1/10th × T1) and 2 ms (> 1/10th × T1) this scatter is
avoided at the cost of at most ~ 10% of the time curve (Figure 2.4f and 2.4g).
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Figure 2.4: Effect of deliberate variations to the first pulse delay time (τ) on T1 (a – c) and T1ρ (d –
g) time curves. Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.

Similarly, by decreasing the duration of the last pulse delay time (Figure 2.5) in the
inversion recovery and spin lock pulse sequences a smaller proportion of the relaxation
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time curve is observed. This is due to not employing sufficiently long pulse delay times
to observe the full return of signal to equilibrium.
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Figure 2.5: Effect of deliberate variations to the last pulse delay time (τ) on T1 (a – c) and T1ρ (d –
e) time curves. Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.

The measured standard deviation for time constants generated here (n = 1) from monoexponential fitting of the time curves for first pulse delay times are 0.082 and 0.16 ms for
T1 measurements at 25 and 37 °C respectively and 0.13 and 0.32 ms for T1ρ
measurements at 25 and 37 °C respectively.

For last pulse delay times the range
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differences are 0.21 and 0.53 ms for T1 measurements at 25 and 37 °C respectively and
0.27 and 0.16 ms for T1ρ measurements at 25 and 37 °C, respectively (Table 2.4).
All standard deviations are larger than the natural variance (standard deviation) in the
data with the exception of T1 values at 25 °C when varying the duration of the first pulse
delay time. It can therefore be said that, generally, there was a significant effect on time
constants by varying the relaxation delay time.
2.5.3. Number of data points
An increased number of data points decreases the time between sampling of the
magnetization and allows for more data points around the inflection of the time curve
(Figure 2.6).
The measured standard deviation for time constants generated here (n = 1) from monoexponential fitting of the time curves are 0.047 and 0.00 ms for T1 measurements at 25
and 37 °C respectively and 0.026 and 0.024 ms for T1ρ measurements at 25 and 37 °C
respectively (Table 2.5).

All standard deviations are less than the natural variance

(standard deviation) in the data. It can therefore be said that there was no significant
effect on time constants by varying the number of data points.
2.6. Recommendations
Often the expected T1 or T1ρ is unknown and pulse sequence parameters have to be
chosen based on a best estimate of the time constants and subsequently refined. The
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following recommendations provide a starting point for initial experiments and should
allow for reliable time constants to be generated. These are summarized in Table 2.6.
Table 2.4: Effect of delibarate variations to the first and last pulse delay (τ) times on T1 and T1
values at 1.41 T (60 MHz). Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. (n = 1).
T1 (ms)

T1ρ (ms)

First delay time (τ)
(ms)

25 °C

37 °C

First delay time (τ)
(ms)

25 °C

37 °C

0.2 (<1/10th × T1)

9.81

11.1

0.01 (<<1/10th × T1)

7.90

9.20

1 (=1/10th × T1)

9.78

11.2

0.2 (<1/10th × T1)

8.20

9.70

9.67

10.9

8.07

9.83

-

-

-

× T 1)
2 (>1/10th × T1)

8.00

9.91

First delay variance
(SD)

0.082

0.16

0.13

0.32

Natural variance
(SD)

0.10

0.067

0.042

0.047

10 (>1/10

th

× T 1)

th

1 (=1/10

T1 (ms)

T1ρ (ms)

Last delay time (τ)
(ms)

25 °C

37 °C

Last delay time (τ)
(ms)

25 °C

37 °C

10 (<5 × T1)

9.70

10.0

21 (<5 × T1)

8.28

10.3

9.46

10.8

7.90

10.1

100 (>5 × T1)

9.28

11.0

-

-

Last delay variance
(SD)

0.21

0.53

0.27

0.16

Natural variance
(SD)

0.10

0.067

0.042

0.047

30 (≅ 5 × T1)

40 (≅ 5 × T1)
-

CHAPTER 2. Effect of pulse sequence parameters on T1 and T1ρ

59

Table 2.5: Effect of delibarate variations to the number of data points on T1 and T1ρ values at
1.41 T (60 MHz). Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. (n = 1).
T1 (ms)

T1ρ (ms)

# data points

25 °C

37 °C

25 °C

37 °C

8

9.80

11.4

8.10

9.80

16

9.75

11.4

8.10

9.85

32

9.69

11.4

8.15

9.80

64
# data point (SD)

9.77
0.047

11.4
0.00

8.14
0.026

9.81
0.024

Natural variance (SD)

0.10

0.067

0.042

0.047

2.6.1. Relaxation delay (RD) times
It has been demonstrated that time constants were not affected significantly (standard
deviation was less than the standard deviation due to natural variation in the data) by the
relaxation delay times examined including those less than the suggested ideal value of 10
× T1 where the magnetization range covered becomes narrower. However, a relaxation
delay time of 10 × T1 is more conventional to ensure full relaxation before subsequent
scans and is therefore recommended. It should be noted that when using the spin locking
pulse sequence long pulse delay times are sometimes necessary to observe the full
relaxation time curve.

This necessitates long relaxation delay times which are

automatically imposed by the instrument and are typically much greater than 10 × T1. In
these cases, the minimum allowable relaxation delay time should be used to avoid
excessively long experiment times.
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Figure 2.6: Effect of deliberate variations to the number of data points on T1 (a – d) and T1ρ (e –
h) time curves. Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.
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Table 2.6: Recommended pulse sequence parameter values for determinations of T1 and T1ρ.

Pulse sequence parameter

Inversion recovery

Spin locking

= 10 × T1

= 10 × T1
or minimum
allowable ≥ 10 × T1

First pulse (ms)

< 1/10th × T1

> 1/10th × T1

Last pulse (ms)

> 5 × T1

> 5 × T1
or maximum allowed
(40 ms)

16

16

Relaxation delay time (s)

Time delays

Number of pulse delays for monoexponential behavior

2.6.2. Pulse delay times
These results demonstrate that significant variation in time constant values (standard
deviation greater than the standard deviation due to natural variation in the data) were
observed when different proportions of the relaxation time curve are measured by varying
the first and last pulse delay times. Additionally, scatter of data points is possible with
pulse delay times that are too short. First and last pulse delay times are sample specific
parameters and therefore exact values are not recommended.

However, it is

recommended that time constants be generated by measuring as much of the time curve
as possible that allows scatter to be avoided. Therefore, first and last pulse delay times of
< 1/10th × T1 and > 5 × T1 respectively are recommended when determining T1 values
with the inversion recovery pulse sequence and > 1/10th × T1 and > 5 × T1 respectively
when determining T1ρ values with the spin lock pulse sequence. It should be noted that a
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last pulse delay > 5 × T1 is not always possible due to instrument limitations to prevent
hardware failure. In this case the maximum allowable should be employed. Reliable
time constants may be generated with longer first pulse and shorter last pulse delay times,
however, the recommended values allow for as much of the time curve as possible to be
measured.
2.6.3. Number of data points
It has been demonstrated that time constants were not affected significantly (standard
deviation was less than the standard deviation due to natural variation in the data) by the
number of data points ranging from between 8 – 64. However, the recommended number
is 16 as this provides more data around the inflection of the time curve whilst keeping
instrument and operator time to a minimum.
2.7. Conclusions
When deliberate variations were made to the suggested “ideal” pulse sequence parameter
values for the three parameters investigated good fittings were generally still observed
and time constants within did not vary by more than the natural variation in the data. The
exception was when an insufficient proportion of the time curve was measured by
varying the first and last pulse delay times. This suggests that this parameter is most
critical for obtaining reliable time constants, more so than the number of data points
along the time curve and the relaxation delay time employed. By investigating the effect
the parameter values have on time constants the values in Table 2.6 are recommended.
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These should provide accurate time constants that do not vary by more than the natural
variation in the data and ensure confidence in NMRD profiles generated from them.
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CHAPTER 3. EFFECT OF SPIN LOCK FIELD STRENGTH (γB1) ON THE
ROTATING FRAME LONGITUDINAL RELAXATION RATE CONSTANT (R1ρρ)
3.1. Establishing the γB1 independency of R1ρ
Jordan and co-workers70 wrote a comprehensive paper describing the effect of a hydrated
paramagnetic ion, undergoing solvent exchange, would have on the rotating frame
longitudinal relaxation rate constant (R1ρ) of bulk solvent nuclei (Equation 3.1), in which
R2W is the laboratory frame transverse relaxation rate constant of the solvent water; q the
number of water molecules bound to the paramagnetic ion; [M] the concentration of the
metal ion, τM the average water residence lifetime of a coordinated water molecule; R1M
and R2M are the laboratory frame longitudinal and transverse relaxation rate constants of
the coordinated water, respectively; ∆ωM is the difference in Larmor frequency between
coordinated and solvent water protons; and ω1 is the Rabi frequency of the spin lock
pulse). The magnitude of the spin lock field (B1) is given by Equation 3.2.
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Due to the isotropic f shell electronic configuration of the Gd3+ ion it does not induce a
hyperfine shift. This means that ∆ωA will be close to zero, at the same time the high

CHAPTER 3. Effect of γB1 on r1ρ

65

paramagnetism of Gd3+ means that R2M will be very large. This invokes the following
condition identified by Jordan and co-workers.
u

A

≫ ∆]A

(3.3)

In the presence of Gd3+ ions this condition is met and Equation 3.1 simplifies to;
u4˜ = u

™+
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(3.4)

If Equation 3.4 is correct then there should be no dependence of R1ρ on the spin lock field
strength characterized in the above equations by the Rabi frequency (ω1).
Expressed as rotating frame longitudinal relaxivity (r1r), Equation 3.4 becomes Equation
3.5.
k … ×4šC…
J
4
… h šC…

*4˜ = ƒƒ.„ Ik
2

(3.5)

To verify this theory, at low field (0.47 and 1.41 T, 20 and 60 MHz respectively) the
rotating frame relaxation time constants were measured and plotted as the rate constant
against the spin lock field strength (γB1) for 100 mM solutions of ProHance (cyclic) and
Magnevist (linear) in PBS at 25 and 37 °C. Due to longer SL pulses that can be played
out by more powerful superconducting instruments, high field experiments (14.1 T, 600
MHz) were performed with a less concentrated (5 mM) solution of Dotarem (cyclic) in
PBS at 25 °C.
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3.2. Modulation of the strength of the spin lock field (γB1)
The flip angle (θ) of a RF pulse, in this case the spin lock pulse, is proportional to its
strength (γB1) and duration (τ) as shown in Equation 3.6.
=

40

(3.6)

To achieve a pulse angle of 90° the Bruker minispec instrument requires a pulse of
duration 2.26 µs. From Equation 3.6 the strength of this pulse, expressed as frequency
with units of kHz, can be determined as follows;
¡ 1
4
×
=
× 2.26
2 2¡
2¡
¢e !£ ,ℎ+,

∴

1000
=
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4
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4
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d

4

-g¤ = 110.6 -g¤

Although correctly calculated, this strength, 110.6 kHz, seems high.

This value

represents a large pulse power for the modest minispec instrument to generate. It is
worth noting that the much more robust 600 MHz spectrometer is set up to prevent the
use of pulse powers in excess of 35 kHz. A resolution with the minispec manufacturer is
ongoing at the time of writing and for the present purposes this value shall be used.
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The strength of the spin lock field was modulated by attenuating its power. Measured in
decibels (-dB), power attenuation describes the relationship between two power quantity
values where as shown in Equation 3.7 where; Pin is input power, Pout is attenuated power
and the factor of 10 accounts for a dB being 1/10th of a bel.
§,,!£¨+,e©£ −6

= 10ª©«4 G ¬l-aH
¬

(3.7)

’®

However, a modified attenuation equation must be used for field quantities, such as field
strength, since the field is generated by current whose square is proportional to power as
shown;
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By substituting the power ratio for a field quantity such as γB1, the modified attenuation
equation can be derived;
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Unless otherwise stated for our experiments we attenuated the power in 1 dB increments
between -40 – -6 dB, the maximum attenuation permitted by the low fixed field
relaxometer instruments. The Rabi frequencies that characterize the strength of the spin
lock field over this attenuation range correspond to 1.1 – 55.4 kHz.
3.3. Effect of γB1 on R1ρ at low B0 field strengths
All profiles show the same basic features regardless of temperature, field or chelate
structure. From Figure 3.1 it can clearly be seen for ProHance at 0.47 T (20 MHz),
which represents agents based on the cyclic ligand DOTA, that when the strength of the
spin lock field is < 10 kHz the mean R1ρ values are scattered and the standard deviations
of the six measurements are large (Figure 3.1a). As the strength of the spin lock field
increases (γΒ1 > 10 kHz) the mean R1ρ values are more reproducible with lower standard
deviations and essentially independent of γΒ1. From the same plot, it is also apparent that
by increasing the temperature from 25 °C (open circles) to 37 °C (closed circles) the
rotating frame relaxation rates decrease slightly, a consequence of ProHance, like all
other clinical agents studied herein, being in the fast exchange regime. An increase in
temperature is expected to result in an increase in T1ρ, as for T1, due to a shortening of the
correlation time (τc) and less efficient dipole-dipole interactions. On moving to 1.41 T
(60 MHz) comparable observations were made (Figure 3.1b). As was the case for
Magnevist, an agent based on the linear ligand DTPA (Figure 3.1c and d at 0.47 and 1.41
T respectively).
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ProHance (1.41 T)

Magnevist (1.41 T)

Figure 3.1: The dependence of the water proton rotating frame longitudinal relaxation rate
constant (R1p) on the strength of the spin lock field (γB1) for a single PBS pH 7.4 solution of each
contrast agent with a [Gd3+] of 100 mM at 25 °C (open symbols) and 37 °C (closed symbols).
ProHance, 0.47 T (a), 1.41 T (b). Magnevist, 0.47 T (c), 1.41 T (d). Data shown are the mean of
six measurements; the error bars represent the SD of the data. Note: γB1 values calculated from
a 90° pulse duration reported from the minispec instrument. These values are surprisingly large
and suggest the the pulse duration reported is incorrect.

It follows from these experiments that in order to generate accurate and precise R1ρ data,
useful for creating NMRD profiles, effective spin locking must occur, rendering R1ρ
independent of γB1. From this data this appears to occur with a minimum spin locking
field strength (γB1) of ~ 10 kHz, however, this value is unrealistic and we demonstrate in
the next section that it is possible to spin lock with a pulse of a few hundred Hz.
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A limitation of the experimental design was a lack of randomization. For each agent,
temperature and B0 field strength the time constants were measured sequentially, starting
at high powers and working towards lower powers. Moreover, the software measures
signal intensity as a function of increasing pulse delay times rather than sampling the
pulse delay times randomly. Randomization to reduce bias from other experimental
factors would add a higher degree of validity to the claims here that the rotating frame
longitudinal relaxation rate constant is independent of the strength of the spin lock pulse.
The raw time curve data is not routinely saved by the low field minispec instrument
software used for these experiments and therefore could not be shown. As a result, it was
not available for offline processing. This could have provided a means to rule out any
biexponential or multiexponential behavior as a source of contribution to the observed
independence of R1ρ on γB1.
3.4. Effect of γB1 on R1ρ at high B0 field strengths
Our high field (14.1 T, 600 MHz) γB1 dependency plot (Figure 3.2) shows similar facets
to those observed at low B0 fields (Figure 3.1). Namely, the rotating frame longitudinal
relaxation rate (R1ρ) of a 5 mM solution of Dotarem (cyclic-type agent) studied shows
greater scatter at low spin lock field strengths. This again is reduced, as is the error
associated with the data, as the strength of the spin lock pulse is increased.

It is,

however, noteworthy to point out some differences from the equivalent low field
experiments. The strength of the spin lock pulse required to effectively lock the spins at
high B0 field is far less, and much more realistic, than those determined from our low
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field experiments, with R1ρ values stabilizing at about 500 Hz. Additionally, the R1ρ
values, and their associated errors, are significantly reduced at 14.1 T (600 MHz). Lastly,
as a result of the increased precision and reduced errors in our high field data a notable
trend was observed in the high field data. From the point the R1ρ data becomes stable to
the end of the range of field strengths studied (~ 500 – 20000 Hz) the R1ρ values decrease
by approximately 5%. Although this is not an expected trend we believe the observation
is not due to any limitation in the theory and offer two possible explanations for which
both may contribute to this observation. Firstly, with the relatively long spin lock pulses
(relative to those required at low field with higher Gd3+ concentrations) required to
observe full signal decay and the incremental decrease in attenuation, buildup of heat
from many successive experiments could be responsible for the observation. In unrelated
experiments (not reported) significant increases in sample temperature were observed
when long spin lock pulses were being employed. Secondly, at high B0 field strengths
the reduction of the effective field by the application of a spin lock pulse may be limiting.
As a result, as the spin lock field strength increases the Rabi frequency may approach the
Larmor frequencies in which dispersion of R1 occurs due to R1M and R2M dependencies
giving rise to the observed decreases in r1ρ.
The reduced spin lock field strength required to effectively lock the spins at high B0 fields
compared to low B0 fields as a consequence of two factors. First, the magnetic field
homogeneity of the low field instruments is less than that of the high field
superconducting spectrometers used in this study since the low field instruments are
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absent of shim stacks capable of tuning the field homogeneity. Accordingly, the line
width of the water proton resonance will be greater at low B0 field strength. Secondly,
due to other limitations of the low field instruments the length of the maximum spin lock
pulse duration capable of being employed is substantially shorter than that achievable
with the high field instruments. As a result, higher agent concentration was necessary
and this also contributes to the increased line width of the signal.
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Figure 3.2: The dependence of the water proton rotating frame longitudinal relaxation rate
constant (R1p) on the spin lock field streng th (γB1) for a single PBS pH 7.4 solution of Dotarem
with a [Gd3+] of 5 mM at 14.1 T (600 MHz) and 25 °C. Data shown are the mean of six
measurements; the error bars represent the SD of the data.

As for our low B0 field strength study, our high B0 field strength study was conducted by
measuring rotating frame relaxation time constants and plotting the rate constant as a
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function of the spin lock field strength (γB1). However, unlike the low field instruments,
the high resolution instrument allows for a Fourier transformed spectrum to be obtained
as described in section 1.6.2.

Figure 3.3 shows raw data, sampled from the sixth

repetition of the analysis of the Dotarem sample, for a select number of spin lock field
strength values (γB1) used to generate Figure 3.2. The frequency domain spectrum shown
for each γB1, corresponds to the FID produced from the acquisition of the pulse sequence
with the shortest time delay in the experiment. The complete time curve is shown as the
overlay along with the respective time and rate constant. This figure demonstrates that
the time curves, generated from the decay of the signal intensity of the spectrum with
subsequent delay times, allow for full decay of the signal to be observed and that the
observed data is well fitted by Equation 1.24 thus providing reliability of the data in
Figure 3.2.
3.5.

A comparison between spin locking and CPMG with short pulse delay times

The CPMG pulse sequence for determining laboratory frame transverse relaxation time
constants (T2) can be likened to a spin lock pulse sequence if the variable pulse delay (τ),
the delay time between the 180° pulses of the echo train, is very short. In such a situation
the 180° refocusing pulses can be considered to be permanently on. The difference,
however, being that the 180° refocusing pulse of the CPMG sequence is a ‘hard’ pulse
(high power and short duration) that undergoes many phase changes whereas the spin
lock pulse is ‘soft’ (low power long duration) and does not change phase whilst
employed.
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Figure 3.3: Sample raw data for the n=6 determination of R1ρ for several pulse strengths used to
prepare Figure 3.2. Spectra were obtained from the FT of the FID from the acquisition with
shortest time delay (τ). Time (T1ρ) and rate (R1ρ) constants are also shown.
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Given their similarity it was important to compare time constants generated from
relaxation data obtained from both pulse sequences. The same PBS solution of Dotarem
prepared at a Gd3+ concentration of 25 mM used for the experiments described in Chapter
2 was used.

We limited investigations to our 20 MHz (0.47 T) fixed low field

relaxometer and measurements were only made at the historically relevant temperature of
25 °C. For this experiment we measured T2 with a series of different pulse delay times
keeping the total experiment time constant by varying the number of data points. It was
only possible to investigate a limited range of τ values for the CPMG pulse sequence, due
to a minimum limit of 40 ms. The time constants were plotted as a function of the
variable pulse delay time (τ) and compared to the rotating frame longitudinal relaxation
time constant for the same sample (Figure 3.4). Pulse powers for all measurements were
set to 6 dB for continuity.
We have demonstrated (Figure 3.4) that over the range of pulse delay times investigated
T2 did not tend to T1ρ as τ varied. In fact, there was no significant change in the T2 value
at all. The standard deviation of mean T2 values (0.05 ms) was less than the natural
variation of the data for the similar time constant, T1ρ, at 25 °C on the same instrument
determined in chapter 2 (Table 3.1). This suggests that a CPMG pulse sequence with
short pulse delay times is not equivalent to a spin locking pulse sequence, a likely
consequence of the CPMG pulse sequence employing 180 refocusing pulse with
alternating phase which does not result in spin locking.
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Figure 3.4: The dependence of the laboratory frame transverse relaxation time constant (T2) on
the variable pulse delay time (τ) for a single PBS pH 7.4 solution of Dotarem with a [Gd3+] of 25
mM at 0.47 T (20 MHz) and 25 °C. The filled circle is the respective rotating frame longitudinal
relaxation time constant (T1ρ). Data shown are the mean of three measurements. Error bars
representing the SD of the data were omitted for clarity but all were smaller than the markers.
The line throught the T2 data is to guide the eye only.

Table 3.1: Effect of the pulse delay time (τ) on mean T2 values (n = 3) at 0.47 T (20 MHz).
T2 (ms)
Pulse delay time (µs)

25 °C

40

7.26

70

7.24

100

7.26

150

7.28

200

7.27

500

7.23

Pulse delay time SD
Natural variance SD (T1ρ)

0.018
0.042

CHAPTER 3. Effect of γB1 on r1ρ

77

3.6. Conclusions
The rotating frame relaxivity of Gd3+-based CAs have been shown to be essentially
independent of the magnitude of the B1 field used to effect spin locking.

This is

consistent with previously reported theory as predicted by Jordan and co-workers.70 This
result is important because it allows the value of γB1 to be neglected when comparing
rotating frame relaxivities of Gd3+-based CAs across several B0 fields. Moreover it seems
that a CPMG pulse sequence with short variable pulse delay times and a spin locking
pulse sequences do not measure the same relaxation mechanism.
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CHAPTER 4. A COMPARISON OF LABORATORY (r1) AND ROTATING (r1ρρ)
FRAME LONGITUDINAL RELAXIVITIES FOR q = 1 CLINICAL Gd3+-BASED
CAs
4.1. Establishing the potential benefits of spin locking on relaxivity
Although well described by theory, the laboratory frame relaxivities of clinical Gd3+based CAs are low, typically 4 – 5 mM-1s-1 (Figure 1.15). The low relaxivities arise from
the rapid molecular tumbling of these low molecular weight chelates (short τR) and
practical restrictions on their hydration number (q). These low relaxivities result in high
detection limits for these agents, necessitating high doses. Agents with bulky substituents
have longer τR values, a result of slower tumbling, which increases relaxivity. However,
relaxivity often continues to be limited by water exchange parameters and relaxivity
invariably falls short of the theoretically calculated maximum. Slowly tumbling chelates
with more rapid water exchange rates (1/τM) afford the highest relaxivities, at current
clinical imaging fields. However, clinical imaging is being performed at increasingly
higher magnetic field strengths and the optimal τM value for r1 relaxivity is found to
decrease as B0 increases.30 Furthermore, we have recently shown that the relationship
between water exchange, molecular tumbling and relaxivity in Gd3+ chelates is more
complex than previously appreciated,74 as a result the theoretical relaxivity potential may
be somewhat lower than previously thought. Improvements in detectability could also be
made by increasing the hydration number (q) of the complex. Through opening up
additional coordination sites to water relaxivity increases, however, this is at the cost of
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reduced chelate stability. Even if a new “gold standard” agent were to be designed that
could afford high relaxivities at high fields a lengthy and costly approvals process would
ensue.
It has been conceived elsewhere75-80 that more significant gains in agent detectability may
be possible by imaging at lower effective B0 fields where relaxivity is likely to be greater.
One method to produce such an image is to generate contrast based on the rotating frame
longitudinal relaxation time constant (T1ρ). T1ρ contrast is generated by employing a
weak spin locking pulse parallel to the net magnetization in the x,y-plane and measuring
the decay of transverse magnetization in the rotating frame of reference as a function of
the spin locking time. Time constants generated in this manner are expected to be
characteristic of those measured at low fields. If proven successful this technique would
have the added benefit of a relatively quick adoption in to clinical practice. Moreover, if
performed in the presence of a large external static B0 field this would allow the s/n
advantages of these fields to be maintained.81
At the time of writing very few reports pertaining to this hypothesis exist.82-85 With the
exception of one publication investigating spin locking with Ablavar,82 the focus has
solely been on Magnevist and the study of imaging metrics such as contrast and contrast
to noise ratio (CNR)83-85 rather than the specific effect on relaxivity, a key indicator of
CA effectiveness and determinant of agent detectability.
Accordingly, we set out to conduct a thorough investigation into the effect of spin
locking on the relaxivity of seven q = 1 clinical Gd3+-based CAs by generating and
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comparing, under identical conditions, r1 and r1ρ relaxivities as a function of B0 in the
form of NMRD profiles.

Due to structural similarities of OptiMARK and

Eovist/Primovist to Ominscan and MultiHance respectively, these agents were not
studied. NMRD profiles for the seven agents were grouped according to the three
structural categories identified in Table 1.1; linear, macrocyclic and bulky. Samples of
the agents were prepared in phosphate buffered saline pH 7.4 and relaxivities determined
over a range of B0 field strengths, 0.47 – 14.1 T (20 – 600 MHz respectively), at both 25
and 37 °C.
4.2. Comparison of r1 and r1ρ for linear and macrocyclic q = 1 clinical Gd3+-based CAs
With the exception of Gadavist, whose relaxivities are slightly elevated over the others,
there is little observable difference between the NMRD profiles generated for linear and
macrocyclic agents other than the specific relaxivities measured (Figure 4.1). This
demonstrates that there is little effect on both r1 and r1ρ at these fields as a result of the
known differences in electron spin relaxation (T1e/T2e) for both macrocyclic and linear
chelates.86 However, for all chelates of these two classes, r1ρ values are higher than r1
values across their entire NMRD profile and both decrease as B0 increases. It is also
noticed that r1ρ falls of slightly less rapidly than r1 does. This shows that by spin locking
it is possible to “recover” relaxivity lost by moving to higher fields for these agents.
However, the gains are fairly modest showing an increase in relaxivity by a factor of just
1.22 at 0.47 T on average, rising to 1.33 at 14.1 T on average (Table 4.1 – 4.4).

CHAPTER 4. A comparison of r1 and r1r for q = 1 clinical Gd3+-based CAs

Macrocyclic agents (25 °C)

Macrocyclic agents (37 °C)
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Figure 4.1: NMRD profiles of the linear and macrocyclic clinical contrast agents studied herein at
25 °C (A & C) and 37 °C (B & D) in PBS: laboratory frame data (r1) are presented in red (closed
symbols); and rotating frame data (r1ρ) are presented in blue (open symbols); ω1 = 35 kHz (0.47
and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). A & B: macrocyclic
agents: Dotarem (squares); ProHance (diamonds); Gadovist (circles). C & D: linear agents:
Magnevist (diamonds); Omniscan (circles). Lines through the data are to guide the eye only.
Data shown are the mean of six measurements; error bars representing the SD of the data were
omitted for clarity, all were smaller than the markers.

At both clinical (0.47 – 1.41 T) and research (9.4 – 14.1 T) field strengths, if a linear or
macrocyclic agent is desired with high relaxivity then it is clear from Figure 4.1a and b
that the agent of choice would be Gadavist and that a spin locking pulse should be
applied. However, from Tables 4.1 – 4.4 it is clear that although Gadavist has the highest
relaxivity of all the linear and macrocyclic agents, with or without spin locking,

herein at low field and their calculated ratios. Mean represents the average difference for the specified category of agents.

0.47 T
r1 (mM s )
r1ρρ (mM-1s-1)
4.60
5.72
4.53
5.79
5.28
6.79
5.06
6.07
4.64
5.12
-1 -1

Macrocyclic
25 °C
Linear

Dotarem
ProHance
Gadovist
Magnevist
Omniscan
Mean

r1ρρ/r1
1.24
1.28
1.29
1.20
1.10
1.22

1.41 T
r1 (mM s )
r1ρρ (mM-1s-1)
3.96
5.07
4.01
5.01
4.85
6.20
4.33
5.59
4.15
4.66
-1 -1

r1ρρ/r1
1.28
1.25
1.28
1.29
1.12
1.24
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herein at low field and their calculated ratios. Mean represents the average difference for the specified category of agents.

0.47 T
r1 (mM s )
r1ρρ (mM-1s-1)
3.74
4.68
3.79
4.63
4.50
5.67
4.18
5.05
4.20
4.60
-1 -1

Macrocyclic
37 °C
Linear

Dotarem
ProHance
Gadovist
Magnevist
Omniscan
Mean

r1ρρ/r1
1.25
1.22
1.26
1.21
1.10
1.21

1.41 T
r1 (mM s )
r1ρρ (mM-1s-1)
3.18
4.04
3.20
4.03
4.06
4.96
3.47
4.47
3.62
4.12
-1 -1

r1ρρ/r1
1.27
1.26
1.22
1.29
1.14
1.24
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herein at high field and their calculated ratios. Mean represents the average difference for the specified category of agents

Macrocyclic
25 °C
Linear

Dotarem
ProHance
Gadovist
Magnevist
Omniscan
Mean

9.4 T
r1 (mM-1s-1)
r1ρρ (mM-1s-1)
3.79
4.95
3.31
5.04
4.42
6.35
4.21
5.91
3.58
4.74

r1ρρ/r1
1.31
1.52
1.44
1.40
1.32
1.40

14.1 T
r1 (mM-1s-1)
3.49
3.48
4.23
4.18
3.54

r1ρρ (mM-1s-1)
4.56
4.83
6.05
5.65
4.43

r1ρρ/r1
1.26
1.39
1.43
1.35
1.25
1.34
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herein at high field and their calculated ratios. Mean represents the average difference for the specified category of agents.

9.4 T
r1 (mM s )
r1ρρ (mM-1s-1)
2.73
3.70
2.64
3.84
3.66
5.08
3.36
4.46
3.02
4.07
-1 -1

Macrocyclic
37 °C
Linear

Dotarem
ProHance
Gadovist
Magnevist
Omniscan
Mean

r1ρρ/r1
1.36
1.45
1.39
1.33
1.35
1.37

14.1 T
r1 (mM s )
r1ρρ (mM-1s-1)
2.61
3.48
2.73
3.70
3.57
4.86
3.24
4.33
3.03
3.80
-1 -1

r1ρρ/r1
1.33
1.36
1.36
1.34
1.25
1.33

CHAPTER 4. A comparison of r1 and r1ρ for q = 1 clinical Gd3+-based CAs

Table 4.4: Raw r1 and r1ρ data at 37 °C used to generate the NMRD above for linear and macrocyclic clinical agents studied

85

CHAPTER 4. A comparison of r1 and r1ρ for q = 1 clinical Gd3+-based CAs

86

the observed increase by applying a spin locking pulse is not necessarily proportional to
the magnitude of the laboratory frame values. For example, at 25 °C and 9.4 T the
relaxivity of ProHance increases from 3.31 mM-1s-1 to 5.04 mM-1s-1 (a factor of 1.52)
whereas Magnevist increases from 4.21 mM-1s-1 to 5.91 mM-1s-1 (a factor of 1.40) and
Gadovist increases from 4.42 mM-1s-1 to 6.35 mM-1s-1 (a factor of 1.44). From the values
in Table 4.2, if Gadavist is selected for a high field imaging application, on average, the
relaxivity using a spin locking pulse increases by a factor of 1.68 when compared to
values obtained from other linear and macrocyclic agents without spin locking.
Values of r1 and r1ρ used in Figure 4.1 were obtained by measuring the laboratory and
rotating frame relaxation time constants (Ti), where i = 1 or 1ρ, provided by fitting the
raw time curve data, comparable to those shown in chapter 3, to the relevant fitting
equations. From these, relaxivity plots were generated by plotting the rate constant (1/Ti)
as a function of [Gd3+]. Linear regression analysis of these plots affords the relaxivity as
the slope, according to the linear form of Equation 1.17. A sample of typical relaxivity
plots generated to determine relaxivities for Figure 4.1 are provided in Figure 4.2 and
demonstrate excellent correlation coefficients typically >0.999.

4.3. A comparison of r1ρ for linear and macrocyclic chelates to simulated theory
To determine if the data observed is a true reflection of theory the relevant parameters
required to simulate rotating frame NMRD profiles are required to be identified. For this,
further analysis of the work set out by Jordan and co-workers is required.
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Figure 4.2: Sample relaxivity (r1) plots for the macrocyclic class of clinical agents. Data shown
are the mean of six measurements with the mean relaxivity (slope) for each agent shown in the
legend. R2 for all agents are > 0.978. Error bars representing the SD of the data were omitted for
clarity, all were smaller than the markers.
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The dependence of r1ρ in the presence of a Gd3+ ion was previously derived in Chapter 3
(Equation 3.5) and is re-stated below.
*4˜

» u A × 1š0A
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¸
º
55.6 u4A + 1š0
A

It can be seen that by spin locking a component of laboratory frame transverse relaxation
(R2M) is introduced and dominates over the laboratory frame longitudinal relaxation
component (R1M). R2M and R1M, the transverse and longitudinal relaxation rate constants
respectively, are defined in the theory of Solomon-Bloembergen-Morgan. R2M is shown
below (Equation 4.1) considering only dipolar contribution; the scalar contribution is
considered negligible as it is so small.87 Similarly, R1M, previously described in Chapter
1 (Equation 1.20) is also shown for ease of reference. Terms in both R2M and R1M are the
same as previously described.
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R2M has a larger dependence on the longitudinal correlation time constant (τC1) than R1M,
suggesting r1ρ should be more dependent on τR and τM, according to Equation 1.19.
Equations 1.19, 1.20, 3.5 and 4.1 were used to simulate the rotating frame NMRD
profiles of Magnevist and Dotarem, the “original” and “gold standard” agents, using well
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established physiochemical parameters at 25 °C obtained from decades of studying their
laboratory frame NMRD.50 The observed data generated here was plotted against the
theoretical simulation and is shown in Figure 4.3. It can be seen that the observed data
(open symbols) agrees well with the simulations (lines), and that from approximately 20
MHz (0.47 T) to 600 MHz (14.1 T) the simulation are almost entirely independent of B0,
a consequence of the dominance of R2M in the r1ρ equation (Equation 3.5). In comparison
to simulations for r1 (Figure 1.15) over the same range of B0 fields, the r1ρ simulations
decrease much less rapidly, confirming our observations.

Figure 4.3: Rotating frame NMRD profiles of Magnevist and Dotarem in PBS at 25 °C. The lines
through the data are simulations, using Eqns 1.20, 1.21, 3.5 and 4.1, of the rotating frame NMRD
profile based on literature values of relevant parameters derived from laboratory frame NMRD
analysis;50 Dotarem: q = 1; rGdH = 3.1Å; τM = 250 ns, τR = 68.4 ps, ∆2 = 1 × 1019 s-2; τV = 10 ps;
Magnevist: q = 1, rGdH = 3.1Å; τM = 303 ns, τR = 67.9 ps, ∆2 = 4.4 × 1019 s-2; τV = 24.9 ps; the outer
sphere contribution was measured by analysis of GdTTHA3-.
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4.4. A comparison of r1 and r1ρ for bulky q = 1 clinical Gd3+-based CAs
Comparable experiments and data processing as described above for macrocyclic and
linear agents was performed for bulky agents to determine their relaxivities and NMRD
profiles. Due to the incorporation of bulky substituents to affect their biodistribution,
Ablavar and MulitHance have slightly longer τR values and elevated relaxivities when
compared to the more rapidly tumbling linear and macrocyclic counterparts (Figure 4.4a
and b at 25 and 37 °C, respectively). For this reason the bulky agents fare better than the
linear and macrocyclic agents, particularly at high field, with an increase in relaxivity by
a factor of 1.22 at 0.47 T on average, rising to 1.46 at 14.1 T on average (Table 4.5 - 4.6).

Bulky agents (25 °C)

Bulky agents (37 °C)

Figure 4.4: NMRD profiles of the bulky clinical contrast agents studied herein at 25 °C (A) and
37 °C (B) in PBS: laboratory frame data (r1) are presented in red (closed symbols); and rotating
frame data (r1ρ) are presented in blue (open symbols); ω1 = 35 kHz (0.47 and 1.41 T) and 6924.2
and 17237.0 Hz (9.4 and 14.1 T respectively). MultiHance (diamonds); Ablavar (circles), the
green cross is the r1ρ value calculated for Ablavar from reference.82 Lines through the data are to
guide the eye only. Data shown are the mean of six measurements; error bars representing the
SD of the data were omitted for clarity, all were smaller than the markers.
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As for linear and macrocyclic agents the r1ρ values of bulky agents are higher than r1
values for all fields investigated and both decrease as a function of B0. However, their r1ρ
NMRD profiles decrease significantly more slowly than r1 than was observed for the
linear and macrocyclic agents, especially at lower temperatures.
The observed dependence of r1ρ on the magnitude of the τR value can be rationalized by
referring to the theory described above and equations 1.20, 3.5 and 4.1. These show that
r1ρ is more dependent than r1 on the characteristic correlation time constant (τC1) of the
contrast agent. Of the parameters in Equation 1.21 τR is limiting for Gd3+-based CAs
such as those studied herein in which the fast water exchange regime criteria are met.
Comparable observations were made in the only other report of the use of spin locking
with a Gd3+-based CA at high fields.82

In that report, Buckley and co-workers

investigated spin locking at 4.7 T with Ablavar, known to bind reversibly to serum
albumin, and observed significantly higher R1ρ values when bound than when unbound.
Although Buckley and co-workers do not quantify relaxivities in their study it is evident
that r1ρ values were greater than r1 values. However, from the data presented this
increases both the laboratory and rotating frame relaxivities of the agent.
By applying an analytical model used in a related study,88 we were able to estimate the
bound and free rotating frame relaxivities for Ablavar with BSA, circumventing
limitations of the method in which the data presented by Buckley and co-workers was
generated.

field and their calculated ratios. Mean represents the average difference for the specified category of agents.

0.47 T

25 °C

Bulky

1.41 T

r1 (mM-1s-1)

r1ρρ (mM-1s-1)

MultiHance

6.04

7.46

Ablavar

7.86

9.75

Mean
37 °C

Bulky

r1ρρ/r1

r1ρρ/r1

r1 (mM-1s-1)

r1ρρ (mM-1s-1)

1.24

5.42

6.95

1.28

1.24

7.11

9.63

1.35

1.23

1.29

MultiHance

5.01

5.95

1.19

4.32

5.57

1.29

Ablavara

6.44

7.89

1.23

5.70

8.47

1.49

Mean
a

Free Ablavar

1.21

1.34
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field and their calculated ratios. Mean represents the average difference for the specified category of agents.

25 °C

37 °C

Bulky

Bulky

MultiHance
Ablavar
Mean
MultiHance
Ablavara
Mean
a

9.4 T
r1 (mM-1s-1)
r1ρρ (mM-1s-1)
4.72
7.36
6.84
9.1

Free Ablavar

14.1 T
r1 (mM-1s-1)
r1ρρ (mM-1s-1)
4.45
6.89
5.30
8.39

r1ρρ/r1
1.56
1.33
1.43

3.76
5.64

5.59
6.97

1.49
1.24

3.52
4.53
1.37

5.34
6.44

r1ρρ/r1
1.55
1.58
1.49
1.52
1.42
1.42

CHAPTER 4. A comparison of r1 and r1ρ for q = 1 clinical Gd3+-based CAs

Table 4.6: Raw r1 and r1ρ data at 25 and 37 °C used to generate the NMRD above for bulky clinical agents studied herein at high

93

CHAPTER 4. A comparison of r1 and r1ρ for q = 1 clinical Gd3+-based CA

94

The model we used assumes a 1:1 binding interaction and uses a binding constant derived
empirically (Ka = 12 M-1).89 Fitting the Buckley data to this model gave values of r1ρbound
= 84.8 mM-1s-1 and r1ρfree = 20.8 mM-1s-1. The bound r1ρ value compares favorably with
the bound r1 value reported in literature (16.2 mM-1 s-1) for the same agent with human
serum albumin (HSA) but at slightly lower field and temperature (3 T and 25 °C).
The substantial increase of both laboratory and rotating frame relaxivity on binding to
HSA or BSA is a direct consequence of the increase in the effective molecular weight of
the agent and a lengthening of τR. It is worthwhile commenting on the magnitude of the
free r1ρ calculated in the presence of BSA.

Since the original experiments were

performed in the presence of 4.5% w/v of BSA, an increase in viscosity is likely which
further lengthens τR resulting in elevated relaxivities, particularly in the rotating frame
which we have shown to be more sensitive to τR.
4.5. Summary of relaxivity changes
Figure 4.5 shows that, in the laboratory frame (red), an approximate 20 and 30% decrease
in relaxivity is observed for low molecular weight (solid) and bulky (diagonal lines)
clinical agents respectively when the external field strength is increased from 0.47 T
(~0.5 T) to 14.1 T. This is a consequence of these agents having comparable laboratory
frame relaxivities at 14.1 T, whereas at 0.5 T bulky agents have higher laboratory frame
relaxivities. Figure 4.5 allows for a better appreciation of the increases in relaxivity by
spin locking clinical agents demonstrated in Figures 4.1 and 4.4. At 0.5 T (purple) the
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increase is modest for both low molecular weight and bulky agents with an increase of
approximately 20% for each. At 14.1 T (green) more substantial increases are observed,
with low molecular weight agents increasing by approximately 35% and bulky agents
increasing by approximately 65%. As discussed previously, the increased gains at higher
fields are a result of a less rapid decrease in r1ρ as a function of B0 than that observed for
r1 (Figure 4.1 and 4.4).
By comparing the change in relaxivity between low molecular weight agents (short τR)
and bulky agents (long τR) Figure 4.10 clearly demonstrates our finding that r1ρ is more
sensitivity than r1 to the rotational correlation time (τR), particularly at high field. Figure
4.5 also demonstrates that by spin locking at the high field strengths of the future, the loss
of relaxivity observed by remaining in the laboratory frame (red) can not only be
recovered, but increased (blue). Additionally, this increase occurs to a greater extent for
bulky agents (~10% increase in relaxivity) than for low molecular weight agents (~5%).
4.6. Conclusions
We were able to demonstrate in the presence of an optimized spin lock pulse that
relaxivity lost on moving to higher B0 field strengths was able to be “recovered” across
all B0 field strengths studied and for all Gd3+-based CAs in current clinical use at both 25
and 37 °C.

For now, it remains to be seen if these findings will afford increased

detectability and reduced limits of detection of these agents.
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Figure 4.5: Percent change in relaxivity at 25 °C by spin locking (rot. frame) at low field (Purple),
high field (green) and over the entire range of field strengths studied (blue) for low molecular
weight agents (solid) and bulky agents (diagonal lines). For reference the percent change in
relaxivity without spin locking (lab. frame) over the entire range of field strengths studied (red) is
also shown for the same agents.

However, it is known that the effect the spin locking pulse will have on inherent rotating
frame relaxation rate constants (R1ρ) of tissue at these fields will play a role in achieving
this particular goal. It can be theorized that since spin locking has a large R2 contribution,
inherent tissue R1ρ values may be comparable. At field strengths up to 2.35 T (100 MHz)
inherent tissue R2 values have been reported to be fairly independent of B0 in both normal
and pathological tissue.90-91

However, at

higher B0 field strengths, such as those
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investigated herein, inherent tissue R2 values have been shown to increase.92
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suggests that agent detectability could be increased at such fields as a result of the less
rapid decrease in relaxivities observed at these high fields by spin locking.
Our finding that the rotating frame relaxivity (r1ρ) is especially sensitive to the rotational
correlation time (τR) is of particular interest. This effect is more pronounced at high B0
fields, where substantial loss of relaxivity is observed and to which future clinical
imaging is heading. Spin locking is therefore likely to be of interest to researchers in the
field of molecular imaging. In such applications, agents are designed to target large
molecular weight biomarkers thereby increasing their effective molecular weight
substantially. By employing a spin locking pulse with such agents it may be possible, at
high field, to “recover” relaxivity in remarkably larger amounts than any gains possible
from similar agents in the laboratory frame. This hypothesis if proven to be true could
potentially decrease the limits of detection of such agents to levels required for successful
molecular imaging where biomarkers typically exist at very low concentrations.
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CHAPTER 5. EFFECT OF ROTATIONAL CORRELATION TIME (ττR) ON
ROTATING FRAME LONGITUDINAL RELAXIVITY (r1ρρ)
5.1. Establishing the potential for increasing relaxivity by spin locking slow tumbling
nano-encapsulated Gd3+ chelates.
The NMRD profiles for q = 1 clinical Gd3+-based CAs (Figures 4.1 and 4.7) and
summary (Figure 4.10), demonstrate that lost relaxivity on moving to higher B0 fields
could be “recovered” by using a spin locking pulse and measuring the rotating frame
relaxivity (r1ρ). Comparison of r1ρ and r1 NMRD profiles for all three classes of clinical
agents revealed that r1ρ is more sensitive to the rotational correlation time (τR) than r1.
Evidence for this was shown by measuring greater gains in relaxivity on applying a spin
locking pulse with low molecular weight bulky agents that tumble more slowly than were
measured for low molecular weight non-bulky agents. This was particularly apparent at
high B0 fields where substantial loss of laboratory frame relaxivity is typically observed
and towards which clinical imaging is heading. However, due to only a slight difference
in τR between the low molecular weight non-bulky and bulky agents studied, the
relaxivity gains from slowing tumbling were fairly modest.
Using the SBM equations it has been possible to model the inner sphere contribution to r1
and r1ρ for a theoretically “optimized” gadoterate chelate for which τR has been increased
from 68.4 ps to 68.4 ns and τM has been reduced from 250 ns to 25 ns (Figure 5.1).
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Figure 5.1: Nuclear magnetic relaxation dispersion (NMRD) profile, generated by us, plotting the
inner sphere contribution to the laboratory frame (solid line) and rotating frame (dashed-dot-dot
line) longitudinal relaxivity for a theoretically “optimized” gadoterate chelate for which τR has been
increased from 68.4 ps to 68.4 ns and τM reduced from 250 ns to 25 ns. Also shown is the
NMRD profile of gadoterate (dashed line61) plotting the inner sphere contribution to the laboratory
frame longitudinal relaxivity as a function of B0 field.

At around 0.71 T (30 MHz), r1 (solid line) for an optimized gadoterate chelate shows a
steady and continual decrease as B0 increases. This occurs to such an extent that r1
converges at around 4.7 T (200 MHz), the upper limit of current clinical imaging fields,
with the r1 value of a nonoptimal chelate (dashed line) and all contrast agents are found to
behave identically. However, r1ρ (dashed-dot-dot line) increase rapidly from 0.71 T (30
MHz) up to around 4.7 T (200 MHz) after which it increases more slowly up to 23.5 T
(1000 MHz). This demonstrates the potential for r1ρ to become exceedingly high at very
high B0 field strengths if molecular tumbling can be substantially slowed and water
exchange optimized. Spin locking may provide a method for significantly increasing the
detectability of such Gd3+-based CAs. This would be useful in applications such as
molecular imaging where biomarkers exist at very low concentrations.
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5.2. Nanoassembled capsules as a model system for investigating the effect of τR on r1ρ
Novel high molecular weight nanoassembled capsules (NACs) containing a Gd3+-based
CA represent a convenient model for investigating the effect of making τR longer.
Samples of Gd3+ containing NACs were kindly supplied by Annah Farashishiko. The
particular advantage of these capsules are that they afford well-defined, slowly rotating
systems that are uncomplicated by the presence of binding equilibria. We therefore
investigated NACs of different size comparing their r1 and r1ρ values at high B0 field
strengths, 9.4 and 14.1 T (400 and 600 MHz respectively), at 25 °C. Low field r1 values
were also determined; however, due to instrument and sample limitations (short spin lock
pulse durations and low Gd3+ concentrations) it was not possible to determine low field
relaxivity in the rotating frame.
5.3. Mechanism of action of nanoassembled capsules (NACs) incorporating GdDOTP5GdDOTP5-

(DOTP

=

1,

4,

7,

10-tetra-azacyclododecane-

N,N',N'',N'''-

tetrakis(methylenephosphonic acid)) is a highly charged q = 0 chelate with a relaxivity of
4.7 mM-1 s-1 (23 MHz, 25 °C),93 remarkably high considering the contributions are solely
from second and outer sphere water. This has largely been attributed to the ability of the
phosphonate groups to tightly bind water94 and form an ordered second sphere95 with
extensive hydrogen bonding that slows water exchange (1/τM) (Figure 5.2). This
negatively charged anionic chelate forms aggregates with high molecular weight cationic
polymers which when encapsulated with SiO2 form NACs (Figure 5.3).
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Figure 5.2: [GdDOTP]5- a q = 0 complex.

By encapsulating GdDOTP5- with a SiO2 nano-particle the outer sphere contribution to
relaxivity is essentially eliminated rendering the capsules as purely second sphere agents.
Additionally, the second sphere water exchange rate is further reduced by aggregate
formation. The encapsulating shell does not inhibit water exchange to such an extent that
it limits relaxivity, i.e. water remains in the fast exchange regime.93 Second sphere
contributions can be described by SBM theory (used to quantify inner-sphere
contributions) and the typical governing parameters, τM and τR, albeit with an elongated
rGd-H distance. It has been shown that at magnetic field strengths of 0.47 – 1.41 T the
limiting effect of τR is lifted by the lengthening of τR on forming aggregates and NACs
and that under these conditions the laboratory frame relaxivities are elevated.93
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Figure 5.3: Cartoon representation of a Gd3+ based NAC.

5.4. Effect of NAC design parameters on relaxivity
Relaxivity is dependent on the size of the NACs. Smaller NACs give rise to the greatest
gains in relaxivity owing to the increased facility for proton transport between chelate
and bulk water – the result of shorter distances required to travel by the water in order to
cross the capsule shell and transmit the paramagnetic relaxation enhancement to the bulk.
The size of NACs have been shown to be dependent on three critical design parameters:
the charge ratio, the cationic polymer and the solvent system used in their synthesis.93
We chose to study NACs prepared with polyallylamine hydrochloride (PAH) in 3:2
MeCN/H2O at a charge ratio (R) of 0.3, 0.5 and 1 with the penta-anionc chelate
(GdDOTP5-).

These design parameters were chosen in an effort to maximize their

relaxivities by limiting their size. Representative SEM images of NACs at each charge
ratio studied are shown in Figure 5.4 and their respective relaxivities in Table 5.1.
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(a) R = 0.3

Figure 5.4: SEM of PAH-GdDOTP5--based NACs prepared in MeCN/H2O, 3:2 at three different
charge ratios (R).

Table 5.1: Laboratory frame longitudinal relaxivity (r1) data for the PAH-GdDOTP5--based NACs
shown in Figure 5.4 (25 °C at 20 MHz).

r1 (mM-1 s-1)

R = 0.3

R = 0.5

R=1

44.39

22.36

7.88

5.5. Effect of γB1 on R1ρ for NACs at high B0 field strengths
According to our model (Figure 5.1 dashed-dot-dot line) the rotating frame longitudinal
relaxivity for an optimized agent should be very high at high fields, therefore, we
investigated the effect of γB1 on R1ρ for NACs at 600 MHz (14.1 T) and 25 °C. For this a
sample of NACs with charge ratio (R) of 0.5 encapsulating GdDOTP5- at a Gd3+
concentration of 0.89 mM in water were used. The strength of the spin locking field
(γB1) was modulated by attenuating the power. For comparison a sample of the free
chelate at a Gd3+ concentration of 5 mM was also investigated. The Rabi frequencies that
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characterize γB1 over the attenuation range sampled corresponded to ~ 200 – 20000 Hz
(NACs) and ~ 400 – 20000 Hz (GdDOTP5-) the results are shown in Figure 5.5.
As expected for the free chelate, similar facets to those observed for Dotarem (Figure
3.2), also a low molecular weight Gd3+-chelate, at high B0 fields can be identified.
Namely, the rotating frame longitudinal relaxation rate (R1ρ) of GdDOTP5- showed very
low errors associated with the data but the mean data point did start to show some scatter
at the lower spin lock field strengths studied. Also, the strength of the spin lock pulse
required to effectively lock the spins at high B0 field was approximately the same, ~ 500
Hz. Again these values are much more realistic than those determined from our low field
experiments. The reduced spin lock field strength required to effectively spin lock,
compared to low field experiments, can again be attributed to the shim capabilities of the
superconducting instrument and the low Gd3+ concentration employed that both
contribute to narrow line-widths and low pulse strengths being required to spin lock.
For the GdDOTP5- encapsulated NACs, the errors associated with the data are again very
low, however the data is shown to be dependent on the strength of the spin lock pulse
with an increasing trend in the rotating frame relaxation rate constant as the power is
decreased up to ~ 1000 Hz where an inflection in the data occurs and R1ρ starts to
decrease as powers continue to decrease to ~ 200 Hz. It is important to keep in mind that
equation 3.1 derived from the theory of Jordan and co-workers70 does not apply in the
case of an encapsulated Gd3+ chelate, the chelate no longer being in simple exchange
with water.
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Figure 5.5: The dependence of the water proton rotating frame longitudinal relaxation rate
constant (R1p) on the spin lock field strength (γB1) for a sample of R = 0.5 PAH-GdDOTP5encapsulated NACs (filled circles) and the free chelate (open circles) in water 14.1 T(600 MHz)
and 25 °C. Data shown are the mean of six measurements; error bars representing the SD of the
data were ommited for clarity but were all less than the markers.

5.6. A comparison of laboratory (r1) and rotating (r1ρ) frame NMRD for NACs
Laboratory (r1) and rotating (r1ρ) frame relaxivities for NACs prepared in this study at
several charge ratios were determined over a range of B0 field strengths and their NMRD
profiles generated. For comparative purposes, free un-encapsulated GdDOTP5- was also
measured (Figure 5.6).
5.6.1. Effect of τR on r1 as a function of B0
As predicted by our model for a theoretically “optimized” agent (Figure 5.1, solid line) r1
values for NACs (Figure 5.6, red open symbols) decrease on increasing the field strength
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from 0.47 T (20 MHz) to 1.41 T (60 MHz) after likely reaching a maximum around 0.7 T
(30 MHz).
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Figure 5.6: NMRD profiles of NACs at 25 °C in water: laboratory (r1) and rotating (r1ρ) frame data
are presented in red and blue (open symbols) respectively. ω1 = 35 kHz (0.47 and 1.41 T) and
6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). Charge ratio (R): 1 (circles), 0.5
(diamonds) and 0.3 (triangles). Laboratory (r1) and rotating (r1ρ) frame data are also presented in
red and blue (closed squares) respectively for un-encapsulated GdDOTP5-. Data shown are the
mean of three measurements; error bars representing the SD of the data were omitted for clarity,
all were smaller than the markers except r1ρ for R = 0.3 NACs which are slightly larger than the
marker. Note: r1ρ for R = 0.3 NACs is based on an estimated [Gd3+], at the time of writing ICPAES data was not avaialble.

The r1 values continue to decrease as the field strength is increased further to 9.4 T (400
MHz) and 14.1 T (600 MHz), again, consistent with the model and presumably due to
sub-optimal water exchange at these fields in the laboratory frame.
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The r1 values for the free chelate (red closed squares) are consistent with the model for a
“non-optimized” low molecular weight non-bulky chelate (Figure 5.1, dashed line) and
previous observations for such chelates studied herein.

Consistent with previous

observations for similar systems by our group,93 r1 values for NACs (red open symbols)
at low field, 0.47 T (20 MHz), are elevated over those of the free chelate (red closed
squares) as is the case at 1.41 T (60 MHz), a consequence of the slowing of rotation. At
high fields, it might have been expected that the r1 values for NACs and free chelate
would converge on approximately the same value. However, this is not the case as
laboratory frame relaxivity values for NACs were found to be lower than the respective
values for the free chelate. This may be the result of two factors. Firstly, by eliminating
the outer sphere contribution by encapsulation, the theoretical relaxivity possible for
NACs would be expected to be lowered by approximately half compared to the free
chelate.22 Secondly, water exchange for the NACs is likely to be slower, due to the
encapsulation that provides a boundary to exchange, and thus less optimum at these field
strengths than for the free chelate.
Also consistent with our previous findings with similar systems93, r1 increases as the
charge ratio, proportional to size, decreases from 1 (red open circles) to 0.5 (red open
diamonds) and further to 0.3 (red open triangles) at low fields. This is a result of more
effective rotational restriction and increased water exchange rates (1/τM) in smaller
NACs. This was not observable at the higher fields studied herein due to the non-
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optimum water exchange rates limiting the relaxivity at these fields leading to negligible
difference in the r1 values between the NACs with different charge ratios.
5.6.2. Effect of τR on r1ρ as a function of B0
With the low field relaxometers the maximum spin lock pulse duration is 40 ms. This
rendered it impossible to determine r1ρ values of NACs at 0.47 and 1.41 T (20 and 60
MHz) with the low sample concentrations employed. The higher concentrations needed
for these experiments were not possible due to material limitations.
From the high field portion of the NMRD profiles in Figure 5.6 (9.4 – 14.1 T, 400 – 600
MHz) it can be seen that r1ρ values for NACs (blue open symbols) are substantially
elevated over the respective r1 values (red open symbols) as observed for the clinical
agents discussed previously. However, and more importantly, the r1ρ values increase on
moving to higher B0 fields rather than decrease as for r1. This finding is in agreement
with predictions made by our model for a theoretically “optimized” gadoterate chelate in
the rotating frame (Figure 5.1, dashed-dot-dot). These results demonstrate the potential
benefits of applying spin locking pulses when imaging using slowly tumbling Gd3+-based
contrast media at high magnetic field strengths.
As observed for other low molecular weight non-bulky agents in this work the rotating
frame relaxivity of the free chelate (blue closed squares) was elevated over the laboratory
frame relaxivity (red closed squares) at all B0 field strengths studied and decreased as B0
increased.
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At high fields r1ρ values for NACs (blue open symbols) are greater than that of the
respective values for the fast tumbling free chelate (blue closed squares). This is again a
consequence of the significantly longer τR for NACs over that of the free chelate.
High field r1ρ values for NACs (blue open symbols) also exhibit a substantial increase as
the charge ratio (size) decreases from 1 (blue open circles) to 0.5 (blue open diamonds)
and further to 0.3 (blue open triangles). Again, this is a consequence of smaller capsules
providing more effective rotational restriction and increased water exchange rates.
5.7. Summary of relaxivity changes
Figure 5.7 shows that, in the laboratory frame (red), an approximate 75, 90 and 95%
decrease in relaxivity is observed for NACs prepared with a charge ratio of R = 1
(checker board), 0.5 (diagonal brick) and 0.3 (confetti) respectively when the external
field strength is increased from 0.47 T (0.5 T) to 14.1 T. For comparison, the change in
relaxivity in the laboratory frame for clinical agents, ~25% (solid), and the GdDTOP5free chelate, ~20% (diagonal lines), are also shown. The greater decrease in relaxivity for
NACs compared to the clinical agents and free chelate is a consequence of NACs having
different, and substantially elevated, laboratory frame relaxivities at 0.5 T over the
clinical agent and free chelate (Figure 5.6) but comparable laboratory frame relaxivities
at 14.1 T. Figure 5.7 allows for a better appreciation of the increase in relaxivity by spin
locking NACs at high field demonstrated in Figure 5.6. At 14.1 T (green) the increases
are exceptionally large for all NACs, approximately 600, 1000 and 1800% for R = 1, 0.5
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and 0.3 respectively, and much more significant than the respective increases observed
for clinical agents (solid) and the free chelate (diagonal lines). The NAC values were
calculated relative to the r1 value for the free chelate since this is greater than the r1 value
for NACs at these fields (Figure 5.6) a consequence of NACs having less optimum water
exchange. This clearly demonstrates the sensitivity of r1ρ to the rotational correlation
time (τR) which is lengthened on decreasing the NAC size, proportional to charge ratio,
due to more effective rotational restriction and increased water exchange rates. Due to
instrument and sample limitations discussed previously, it was not possible to measure
rotating frame relaxivities on our low field instruments, therefore a comparison to r1 at
0.5 T could not be made. Figure 5.7 also demonstrates that by spin locking at the high
field strengths of the future, lost relaxivity that is expected by remaining in the laboratory
frame (red) for clinical agents, free chelate or NACs, can not only be recovered but
increased (blue). Additionally, this increase occurs to a greater extent for NACs (~ 260,
90 and 60% for R = 1, 0.5 and 0.3 respectively) than for clinical agents (~8%) and free
chelate (~ 6%). The decrease in the change in relaxivity for NACs as a function of the
charge ratio (blue) is a consequence of larger increases in r1 at 0.5 T than r1ρ at 14.1 T
(Figure 5.6).
5.8. Conclusions
Rotating frame relaxivities at high fields were found not only to be exceptionally large
compared to those obtained in the laboratory frame (43 mM-1s-1 vs. 1.9 mM-1s-1 for NACs
with a charge ratio of 0.5 at 14.1 T), but also increased as B0 increased.
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Figure 5.7: Percent change in relaxivity at 25 °C by spin locking (rot. frame) at high field (green)
and over the entire range of field strengths studied (blue) for clinical agents (solid), GdDOTP5free chelate (diagonal lines) and GdDOTP5- NACs R = 1 (checker board), R = 0.5 (diagonal brick)
and R = 0.3 (confetti). For reference the percent change in relaxivity without spin locking (lab.
frame) over the entire range of field strengths studied (red) is also shown for the same agents.
Note: the percent change by spin locking NACs at high field was calculated relative to the
laboratory frame relaxaivities of the free chelate which are larger than those for NACs.

They were also found to be substantially elevated over those measured for the free
chelate for which the latter shows a decreasing trend with B0.

The rotating frame

relaxivities measured herein for NACs at high fields are larger anything previously
reported at these fields and were found to be in agreement with our models for a
theoretically “optimized” gadoterate chelate in the rotating frame.
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Laboratory frame relaxivities for NACs were found to be in agreement with our model
for a theoretically “optimized” gadoterate chelate in the laboratory frame. That is, r1
values for NACs are elevated over the free chelate at low fields, 0.47 – 1.41 T (20 – 60
MHz) but drops off dramatically at higher field strengths. At high fields, however, the
laboratory frame relaxivities for NACs were found to be lower than those achievable for
the free chelate. At low fields, as the charge ratio of NACs (inversely proportional to
their size) decreased, the laboratory frame relaxivity was found to increase. This was
consistent with previous finding for similar systems.93 However, little difference in their
laboratory frame relaxivity was observed at high fields.
The use of spin locking, particularly at high fields, may prove beneficial in targeted
molecular imaging applications. For such applications contrast agents are targeted to
large molecular weight biomarkers giving rise to very large effective molecular weights
and long τR values.

This work shows that employing a spin locking pulse could

potentially increase relaxivities beyond values currently obtainable at high fields in the
laboratory frame with comparable agents and may decrease limits of detection to levels at
which biomarkers for disease pathology exist.
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CHAPTER 6. EFFECT OF HYDRATION NUMBER (q) ON ROTATING FRAME
LONGITUDINAL RELAXIVITY (r1ρρ)
6.1. Potential applications of spin locking with hydration numbers (q) ≠ 1
As can be seen from the SBM equation (Equation 1.19) one possible means of increasing
the relaxivity of an agent is to increase its hydration number (q). The hydration number
refers to the number of water molecules in the inner coordination sphere of the metal ion.
It is well established that by opening up extra coordination sites to additional water
molecules the laboratory frame longitudinal relaxivity (r1) of Gd3+-based CAs scales
proportionally. However, it does so at the expense of the thermodynamic stability of the
chelate which has been shown to reduce by up to three orders of magnitude71 and as such
all current clinical Gd3+-based CAs are restricted to just one inner sphere water molecule.
However, many investigations are performed in vitro, ex vivo and/or in vivo using animal
models for which the stability of the CA is a lesser concern.

Moreover, for such

investigations the paramagnetic metal ion is not limited to Gd3+. When looking to the
periodic table for other paramagnetic ions with properties similar to Gd3+, Mn2+ stands
out. Mn2+ has five unpaired electrons, a long electron relaxation time and can bind water
molecules that undergo exchange. In fact, Lauterbur and co-workers used a salt of MnCl2
in dogs to demonstrate the importance of paramagnetic materials for MRI.96 Mn2+ is
capable of replacing the biologically active cation Ca2+ and penetrate cells97 and has
found widespread use in preclinical imaging in manganese enhanced MRI (MEMRI).
Mn2+ also formed the basis of two FDA approved contrast agents, Teslascan, and
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Lumenhance.96 Although Mn2+ is an important biological metal, exposure to elevated
levels has been shown to have neurotoxic effects98 attributed to Mn2+ being internalized
into neuronal cells.99-100 These agents have since been discontinued for clinical practice.
However, there still remains a large body of work in the literature pertaining to the use of
complexes of Mn2+ with various hydration numbers ex vivo and this comprises the field
of MEMRI. This provided us the motivation to study the effect spin locking has on the
relaxivity of agents with a variety of hydration numbers for both Gd3+ and Mn2+-based
chelates.
6.2. Low molecular weight chelates of Gd3+ and Mn2+ as systems for investigating the
effect of q on r1ρ
We restricted our investigations to low molecular weight complexes of Gd3+ and Mn2+
that have approximately the same rotational correlation time (τR). This allowed the effect
on relaxivity of the hydration numbers of the complexes to be studied independent of the
influence of τR, particularly at high fields where τR is non-limiting. Gd3+ and Mn2+ have
nine and six coordination sites respectively and the hydration number of their complexes
is dependent on the number of chelating atoms on the ligand. Chelates of Gd3+ and Mn2+
were prepared with a variety of hydration numbers (Figure 6.1) and their laboratory and
rotating frame relaxivities compared over a range of low and high B0 field strengths, 0.47
(20 MHz) – 14.1 T (600 MHz), at 25 °C.
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Figure 6.1: Ligands for the preparation of low molecular weight Gd3+ and Mn2+ chelates with a
variety of hydration numbers.

6.3. Effect of γB1 on R1ρ for MnCl2 at low B0 field strengths
Unlike the Gd3+ metal ion, the Mn2+ ion induces a chemical shift with characteristically
broad line-widths.101 However, with no ligand field stabilization Mn2+ complexes are
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extremely labile and water exchange is rapid, leading to very large laboratory frame
transverse relaxation rate constant (R2M). Therefore it is hypothesized that the condition

invoked by the use of Gd3+ chelates, i.e. u

A

≫ ∆]A , (Equation 3.3) that renders the

rotating frame longitudinal relaxation rate constant (R1ρ) independent of the spin locking
field strength (γB1), will hold true for Mn2+ chelates. If true, it will again allow the value
of γB1 to be neglected when comparing rotating frame relaxivities of Mn2+-based CAs
across several B0 fields. Therefore, we investigated the effect of γB1 on R1ρ using a 5 mM
solution of MnCl2 in PBS pH 7.4 at 20 MHz (0.47 T) and 25 °C. The strength of the spin
locking field (γB1) was modulated by attenuating the power. The Rabi frequencies
expressed in kHz (ω1) that characterize γB1 over the attenuation range sampled
corresponded to 1.1 – 55.4 kHz and the results are shown in Figure 6.2.
It can clearly be seen that R1ρ is unaffected across almost the entire range of Rabi
frequencies sampled. Only when the γB1 is <1.5 kHz does the mean R1ρ value begin to
change, decreasing as γB1 tends to zero, which as shown by Equation 6.1, where; u4˜
defines the lower power limit (ω1

0) effect on R1ρ – again from the work of Jordan and

co-workers,68 but also explained by others63, 102 – and should tend to R2 values.
u4˜ = u
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+
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(6.1)

It is noteworthy that in comparison to the data for the Gd3+-based CAs at 20 MHz and 25
°C (Figure 3.1a and 3.1c for ProHance and Magnevist respectively) the data for MnCl2
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have much lower associated errors, and effective spin locking occurred at lower powers.
The reduced spin lock field strength required to effectively lock the spins of MnCl2 is a
consequence of narrower line-widths for the signal, a result of a much lower sample
concentration employed due to the potency of MnCl2 at effecting relaxation rates.
It follows from these experiments that in order to generate accurate and precise R1ρ data,
useful for creating NMRD profiles, effective spin locking must occur. From this data this
appears to occur with a minimum spin locking field strength (γB1) of ~ 5 kHz, again an
unrealistic value as a consequence of the likely incorrect pulse duration obtained from the
minispec instrument, vide supra.
Under conditions of effective spin locking, the rotating frame relaxivity of Mn2+-based
chelates is largely independent of the strength of the spin locking field, as was the case
for Gd3+-based CAs.

This suggests that the Mn2+-bound water laboratory frame

transverse relaxation rate constant must therefore be significantly larger than the
chemical shift difference between the metal bound and bulk water protons induced by
Mn2+ (e. !. R

Æ

>> ∆]A . As such, this allows for the comparison of rotating frame

longitudinal relaxivities of Mn2+-based chelates across several B0 fields without
consideration of the effect of the spin locking pulse strength.
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Figure 6.2: The dependence of the water proton rotating frame longitudinal relaxation rate
constant (R1p) on the strength of the spin locking field (γB1) for a 5 mM MnCl2 solution in PBS at
25 °C and 20 MHz. Data shown are the mean of six measurements; the error bars represent the
SD of the data. Note: γB1 values calculated from a 90° pulse duration reported from the minispec
instrument. These values are surprisingly large and suggest the the pulse duration reported is
incorrect.

6.4. A comparison of laboratory (r1) and rotating (r1ρ) frame NMRD for low molecular
weight Gd3+ and Mn2+ agents as a function of hydration number (q)
Laboratory (r1) and rotating (r1ρ) frame relaxivities for low molecular weight chelates of
Gd3+ and Mn2+ with a variety of hydration number prepared in this study were
determined over a range of B0 field strengths and their NMRD profiles generated.
6.4.1. A comparison of r1 and r1ρ for low molecular weight non-bulky Gd3+ complexes
The laboratory frame relaxivities of GdTTHA3- (q = 0), GdDTPA (q = 1) and GdCl3 (q =
9) follow a similar trend to those observed for clinical Gd3+-based CAs (Figure 6.3) in
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that r1 decreases as B0 increases, and increases as the hydration number increases. By
applying a spin lock pulse, rotating frame relaxivities were again larger than the
laboratory frame relaxivities at all field strengths measured (0.47 – 14.1 T, 20 – 600
MHz), increased as a function of increasing hydration number and decreased as B0
increased. It was observed for all three agents that, again, the rotating frame relaxivity
decreased slightly less rapidly than in the laboratory frame. As with clinical agents, the
gain in relaxivity for each chelate by employing a spin locking pulse is fairly modest,
showing an increase in relaxivity by a factor of just 1.10 at 0.47 T for GdTTHA3-, a q = 0
complex, rising to 1.35 at 14.1 T for GdDTPA, a q = 1 complex (Table 6.1). The
magnitude of the increase in relaxivity by applying a spin locking pulse is again not
necessarily proportional to the magnitude of the laboratory frame relaxivity. This can be
seen from the data for the q = 9 chelate GdCl3 at 14.1 T which increases from 10.7 to
13.1 mM-1 s-1 a factor of only 1.22 compared to 1.35 for GdDTPA (Table 6.1).
Moreover, as predicted by SBM theory (Equation 1.9), at all field strengths studied the
laboratory frame relaxivity increases as the hydration number increases. This was also
observed for the rotating frame relaxivities.
6.4.2. A comparison of r1 and r1ρ for low molecular weight Mn2+ complexes
The laboratory frame relaxivities of MnEDTA (q = 0) and MnCl2 (q = 6) follow a similar
trend to those observed for Gd3+ complexes (Figure 6.4) in that r1 decreases as B0
increases, and increases as the hydration number increases. By applying a spin lock
pulse, rotating frame relaxivities were again larger than the laboratory frame relaxivities
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at all field strengths measured (0.47 – 14.1 T, 20 – 600 MHz) and also increased as a
function of increasing hydration number. However, the relaxivities in the rotating frame
for both Mn2+ complexes increase on moving to higher B0 fields rather than decrease as
for r1 and the Gd3+ analogues. By applying a spin lock pulse the relaxivity of MnEDTA,
a q = 0 complex, increases from 4.07 mM-1 s-1 to 13.60 mM-1 s-1 at 0.47 T and 25 °C (a
factor of 3.34).
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Figure 6.3: NMRD profiles of low molecular weight chelates of Gd3+ with varying hydration
numbers studied herein at 25 °C in H2O: laboratory frame data (r1) are presented in red (closed
symbols); and rotating frame data (r1ρ) are presented in blue (open symbols); ω1 = 35 kHz (0.47
and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). GdTTHA3-, q = 0,
(squares); GdDTPA, q = 1, (diamonds); GdCl3, q = 9, (circles). Lines through the data are to
guide the eye only. Data shown are the mean of six measurements; error bars representing the
SD of the data were omitted for clarity, all were smaller than the markers.

complexes studied herein at low and high field and their calculated ratios. Mean represents the average difference for the
specified category of agents.

0.47 T
r1 (mM s )
r1ρρ (mM-1s-1)
2.45
2.70
5.06
6.07
12.72
14.36
-1 -1

25 °C

Low MW
Gd3+
chelates

GdTTHA3- (q = 0)
GdDTPA (q = 1)
GdCl3 (q = 9)
Mean

Low MW
Gd3+
chelates

GdTTHA3- (q = 0)
GdDTPA (q = 1)
GdCl3 (q = 9)
Mean

9.4 T
25 °C

1.10
4.21
10.6

1.30
5.91
13.1

r1ρρ/r1
1.10
1.20
1.13
1.14
r1ρρ/r1
1.18
1.40
1.24
1.27

1.41 T
r1 (mM s )
r1ρρ (mM-1s-1)
2.13
2.40
4.33
5.59
10.20
12.20
-1 -1

14.1 T
0.95
4.18
10.7

1.27
5.65
13.1

r1ρρ/r1
1.13
1.29
1.20
1.21
r1ρρ/r1
1.34
1.35
1.22
1.30
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At 14.1 T and 25 °C the increase is from 3.04 mM-1 s-1 to 41.3 mM-1 s-1 (a factor of 13.6)
(Table 6.2). More substantial gains in relaxivity were observed for the q = 6 MnCl2
complex. At 0.47 T and 25 °C the relaxivity increased from 6.85 mM-1 s-1 in the
laboratory frame to 38.26 mM-1 s-1 in the rotating frame (a factor of 5.59). But, at 14.1 T
and 25 °C the increases was a factor of 31.1 going from 4.99 mM-1 s-1 in the laboratory
frame to 155 mM-1 s-1 in the rotating frame! This is by far the highest relaxivity ever
observed for a discrete metal complex at such a high magnetic field. Like clinical Gd3+based CA, these complexes are in the fast exchange regime. As such the relaxivities of
MnCl2, for example, decrease when the temperature is increased.
In 1984 Keonig and Brown reviewed the implications for NMR imaging (MRI) of
solvent proton relaxation by paramagnetic solutes and its dependence on magnetic field
and chemical environment.103 In that paper the dependence on magnetic field of 1/T1 (R1)
and 1/T2 (R2) of water protons for aqueous solutions of several transition metal ions,
including Mn2+, were determined (Figure 6.5).

SBM theory that explains the field

dependence of 1/ T1 can also be applied to describe 1/ T2. The normalized r1 and r2
NMRD profiles for Mn2+ were shown to be unique from each other and also amongst the
other ions analyzed. At low fields (< ~1 MHz) r1 and r2 values for all ions except Mn2+
are essentially independent of field strength and follow the same trend, however, for
Mn2+ ions an inflection at this point is observed with the relaxivities increasing
substantially as B0 decreases towards 0.01 MHz.
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Figure 6.4: NMRD profiles of low molecular weight Mn2+ chelates with varying hydration
numbers, MnEDTA (triangles) = 0, MnCl2 (circles) = 6, studied herein at 25 °C (open symbols)
and 37 °C (closed symbols) in H2O. Laboratory (r1) and rotating frame (r1ρ) frame data are
presented in red and blue respectively. ω1 = 35 kHz (0.47 and 1.41 T) and 6924.2 and 17237.0
Hz (9.4 and 14.1 T respectively). Lines through the data are to guide the eye only. Data shown
are the mean of six measurements; error bars representing the SD of the data were omitted for
clarity, all were smaller than the markers.

At high fields the trend in r1 for all ions, including Mn2+, are comparable and differ only
by the ratio T1/T2 = 3.5/3. An inflection occurs at around 3 MHz and the relaxivities
decrease as B0 increases. As B0 increases up to ~ 10 MHz, r2 for Mn2+ follows the same
trend as for r1, albeit with larger values. However, at higher B0 values r2 rapidly and
substantially increases.
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studied herein at low and high field and their calculated ratios.

25 °C

37 °C

Low MW
Mn2+
chelates
Low MW
Mn2+
chelates

MnEDTA (q = 0)

0.47 T
r1 (mM-1s-1)
r1ρρ (mM-1s-1)
4.07
13.60

37 °C

Low MW
Mn2+
chelates
Low MW
Mn2+
chelates

3.34

1.41 T
r1 (mM-1s-1)
r1ρρ (mM-1s-1)
3.18
20.68

r1ρρ/r1
6.50

MnCl2 (q = 6)

6.85

38.26

5.59

5.40

58.89

10.91

MnCl2 (q = 6)

5.88

35.30

6.00

4.38

50.70

11.58

3.04

41.3

r1ρρ/r1
13.6

MnEDTA (q = 0)

3.14

38.1

r1ρρ/r1
12.1

MnCl2 (q = 6)

5.05

143

28.3

4.99

155

31.1

MnCl2 (q = 6)

3.73

98.8

26.5

3.66

108

29.5

9.4 T
25 °C

r1ρρ/r1

14.1 T
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Table 6.2: Raw r1 and r1ρ data at 25 and 37 °C used to generate the NMRD above for the low molecular weight Mn2+ complexes

124

CHAPTER 6. Effect of q on r1ρ

125

Unlike the other transition metal ions studied, and Gd3+ ions/chelates, Mn2+ has a large
contribution to relaxation from scalar coupling.104 This is a result of a widely delocalized
electronic wave function for hydrated Mn2+ ions such that the electron spin momenta has
a greater interaction with the bound water protons. Although the scalar interaction is
small compared to the dipole-dipole interaction, the contribution to the NMRD profile is
large due to a 100-fold difference in their correlation times. The characteristic r1 and r2
NMRD profiles for Mn2+ ions are a consequence of this same phenomena.

Figure 6.5: r1 NMRD profiles of aqueous soultions of transition metal ions at 35 °C scaled by the
value of S(S + 1) where S is their spin quantum number. The solid lines through the data are a
result of a least-squares fitting of the data with well established theory appropriate to the
solutions. r2 profiles are not shown for any other ion except Mn2+ since they would be similar to
r1. Mn2+ r2 values (dotted line) were derived from theory and supported by experiment.

CHAPTER 6. Effect of q on r1ρ

126

Since a spin locking pulse incorporates a component of laboratory frame transverse
relaxation (R2M) that is especially sensitive to the scalar contribution as described above
this explains the exceptionally high rotating frame relaxivities obtained herein for our
Mn2+ chelates.
6.5. Conclusions
Only modest gains in relaxivity were measured for the low molecular weight Gd3+
chelates by spin locking and the values decrease as B0 increases as has been observed
previously herein for the structurally similar clinical Gd3+-based CAs. However, very
large gains were observed for Mn2+ agents at all fields and increases as B0 increases due
to their unique magnetic properties. Moreover, the results demonstrate that relaxivity in
the rotating frame scales proportionally with q. We demonstrated that in the rotating
frame relaxivity lost on moving to higher B0 field strengths was able to be “recovered”
across all B0 field strengths studied and for all hydration numbers (q) of Gd3+ and Mn2+
studied.
It has clearly been demonstrated that by combining the spin locking technique with such
Mn2+ agents the potential exists to increase detection limits dramatically. This approach
may prove to be most useful in ex vivo or in vivo animal model studies where the known
stability and toxicity problems associated with these agents is a lesser concern. Such
experiments would contribute to the field of Manganese Enhanced MRI (MEMRI), a
growing area of research accelerated by recent safety concerns of clinical Gd3+-based
agents.105-106
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CHAPTER 7. EXPERIMENTAL SECTION
7.1. Reagents and solvents
All reagents were purchased from commercially available sources unless otherwise
noted. Type I water (18.2 MOhm·cm) was used for the preparation of all solutions of
contrast media and phosphate buffered saline. Phosphate buffered saline (PBS) pH 7.4
(50 mM phosphate buffer with 15 mM NaCl) was prepared by combining 1 M aqueous
sodium dihydrogenorthophosphate solution (7.6 mL), 1 M aqueous disodium
hydrogenorthophosphate heptahydrate solution (42.4 mL) and 5 M aqueous sodium
chloride solution (30.0 mL) and diluting to 2 L with water.
7.2. Instrumentation
Relaxation time constants were determined at low field using Bruker Minispec desktop
relaxometers operating at fixed fields of 20 MHz (0.47 T) and 60 MHz (1.41 T) using a 2
mm broad-band probe with the temperature controlled using the installed Julabo F25-ED
variable-temperature controller.

High field relaxation time constants were determined

using Bruker Avance IIa and III NMR spectrometers operating at 400.13 MHz (9.4 T)
and 599.92 MHz (14.1 T), respectively. Both high field spectrometers were installed
with 5 mm broad-band probes and the temperature was controlled using the installed
variable-temperature

controller

model

2416

with

BCU-05

chiller.
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7.3. Pulse sequences
7.3.1. Inversion recovery pulse sequence
The factory installed inversion recovery pulse sequence was used throughout, this
comprises: 180° inversion pulse – τ variable pulse delay – 90° excitation pulse –
acquisition of FID.
7.3.2. Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence
The factory installed CPMG pulse sequence was used throughout, this comprises: 90°
excitation pulse – τ variable pulse delay – 180° (n) refocusing pulses – acquisition of
FID.
7.3.3. Spin locking pulse sequence
The factory installed spin locking pulse sequence was used throughout, this comprises:
90° excitation pulse – τ variable spin locking pulse duration – acquisition of FID.
7.4. Fitting
All rate constant data acquired at 0.47 and 1.41 T were analyzed using the factory
installed fitting routine. All rate constant data acquired at 9.4 and 14.1 T were fitted offline using a least squares fitting routine in Excel to Equations 1.12 (T1 data), 1.13 (T2
data) and 1.24 (T1ρ).

CHAPTER 7. Experimental

129

7.5. Contrast media stock solution preparations
7.5.1

Clinical Gd3+-based contrast agents

Seven of the nine clinically available Gd3+-based contrast agents were studied. Three
were macrocyclic chelates: gadoterate meglumine (Dotarem, 500 mM), gadoteridol
(ProHance, 500 mM), gadobutrol (Gadavist, 1000 mM). Four were linear chelates: of
which two were low molecular weight: gadopentetate dimeglumine (Magnevist, 500
mM) and gadodiamide (Omniscan, 500 mM); and two incorporated bulky substituents:
gadobenate dimeglumine (MultiHance, 500 mM) and gadofosveset trisodium (Ablavar,
250 mM). All were obtained and studied in their clinical formulations and used as stock
solutions.

Gadoversetamide (Optimark) and gadoxetate disodium (Eovist/Primovist)

were not studied given the structural similarities between these agents and gadodiamide
(Omniscan) and gadobenate (MultiHance), respectively and the likelihood of identical or
similar results for these two pairs. All contrast media were purchased from commercial
sources with the exception of gadoterate which was a gift from Guerbet s.a.
7.5.2

GdCl3

Approximately 5 mL of concentrated HCl (12.1 M) was added to a small quantity of
Gd2O3 to dissolve. The solvent was evaporated by heating at 60 – 80 °C with stirring for
several hours. Several subsequent small aliquots (1 – 2 mL) of HCl (12.1 M) were added
and solvent evaporated in the same manner. After the final evaporation of solvent a
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white crystalline product of GdCl3 was afforded and used ‘as is’. A stock solution of
GdCl3 (109.5 mM) was prepared by dissolving GdCl3 (577.0 mg) in water (20 mL).
7.5.3. MnCl2
A stock solution of MnCl2 (~120 mM) was prepared by dissolving MnCl2 (0.72 mmol,
0.091 g) in water (6 mL).

The actual MnCl2 concentration of this solution was

determined by relaxometry (20 MHz and 25 °C).

For this, the laboratory frame

longitudinal relaxation rate constant for the stock solution and a series of dilute aqueous
solutions were determined. Linear regression analysis of the experimental data using the
least squares method and the known relaxivity for this agent under similar conditions
(7.44 mM-1 s-1)103 using the solver function in Excel afforded the actual concentration of
the stock solution (131.3 mM).
7.5.4. GdTTHA3A stock solution of GdTTHA3- (~50 mM) was prepared by dissolving GdCl3 (0.5161
mmol, 0.1918 g) and H6TTHA (0.5485 mmol, 0.2712 g) in a small volume of water (~3
mL), adjusting the pH to ~5 with dilute solutions of NaOH/HCl and diluting to ~20 mL
with water prior to freeze drying the solution and re-dissolving the GdTTHA3- in PBS pH
7.4 (10 mL). The actual GdTTHA3- concentration of this solution was determined by
relaxometry (20 MHz and 25 °C). For this, the laboratory frame longitudinal relaxation
rate constant for a series of dilute solutions of GdTTHA3- in PBS pH 7.4 were
determined. Linear regression analysis of the experimental data using the least squares
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method and the known relaxivity for this agent under identical conditions (1.7 mM-1 s1 107

)

using the solver function in Excel afforded the actual concentration of the stock

solution (31.31 mM).
7.5.5. MnEDTA
An aqueous stock solution of MnEDTA (56.8 mM) was prepared by mixing MnCl2 stock
solution (3.0 mL, 0.39 mmol) and 100 mM Na2EDTA (3.938 mL, 0.39 mmol).
7.6. Working solution preparations and experimental parameters
7.6.1. Chapter 2. Effect of pulse sequence parameters on longitudinal (T1) and rotating
(T1ρ) frame time constants
For the purposes of determining the effect pulse sequence parameters have on laboratory
and rotating frame relaxation time constants (T1 and T1ρ respectively) a solution (25 mM)
of Dotarem was prepared from the formulated product. Experiments were performed at
25 and 37 °C using a low fixed field Bruker Minispec desktop relaxometer operating at
60 MHz (1.41 T). The factory installed inversion recovery and spin locking pulse
sequences were employed. Except where changed for the purpose of the experiment the
following pulse sequence parameters were used; inversion recovery pulse sequence;
recycle delay = 0.1 s; number of data points = 16; number of averages = 4 and the
inversion pulse delay times ranged from 0.2 – 100 ms. Spin locking pulse sequence;
recycle delay = 4 s; number of data points = 16; number of averages = 4; spin locking
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pulse durations ranged from 2 to 40 ms and the Rabi frequency (ω1) = 20 kHz.
Relaxation time constants were obtained as single measurement determinations.
7.6.2. Chapter 3. Effect of spin lock field strength (γB1) on the rotating frame
longitudinal relaxation rate constant (R1ρ)
For the purposes of B1 power experiments the rotating frame longitudinal relaxation rate
constants (R1ρ) were determined for 100 mM solutions of ProHance and Magnevist in
PBS (0.47 and 1.41 T) and a 5 mM solution of Dotarem in PBS (14.1 T) prepared from
the respective formulated products. The factory installed spin locking pulse sequence
was employed with the following pulse sequence parameters; recycle delay = 4 s; number
of data points = 16; number of averages = 4; spin locking pulse durations ranged from 2 –
20 ms (0.47 and 1.41 T) and 25 to 800 ms (14.1 T). The Rabi frequency (ω1) was varied
from 1.2 kHz to 55.4 kHz (0.47 and 1.41 T) and 209.6 Hz to 17237 Hz (14.1 T).
Relaxation time constants were determined by averaging the values obtained from six
measurements for each value of ω1.
7.6.3. Chapter 4. A comparison of laboratory (r1) and rotating (r1ρ) frame longitudinal
relaxivities for q = 1 clinical Gd3+-based CAs
NMRD profiles were generated from laboratory and rotating frame relaxivity
determinations of each clinically approved agent (Dotarem, ProHance, Gadavist,
Magnevist, Omniscan, MultiHance and Ablavar) in PBS at the four magnetic field
strengths studied (0.47, 1.41, 9.4 and 14.1 T). Relaxivities were determined by linear
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regression analysis of the longitudinal relaxation rate constant as a function of contrast
agent concentration in Excel.
Rotating frame longitudinal relaxation rate constants (R1ρ) were determined on five
solutions of each contrast agent in PBS varying in concentration from 10 to 25 mM (0.47
and 1.41 T) and 5 to 25 mM (9.4 and 14.1 T) with the exception of Dotarem at 600.13
MHz which was measured on five solutions varying in concentration from 1 to 5 mM
solutions. The factory installed spin locking pulse sequence was employed with the
following pulse sequence parameters; recycle delay ≥ 10 × T1; number of data points =
16; number of averages = 4; spin locking pulse durations ranged from 2 to 40 ms (0.47
and 1.41 T) and 2.4 – 1600 ms (9.4 and 14.1 T) and the Rabi frequency (ω1) = 35 kHz
(0.47 and 1.41 T) and 6924.2 and 17237.0 kHz (9.4 and 14.1 T respectively).
For purposes of generating laboratory frame NMRD profiles longitudinal relaxation rate
constants (R1) were determined using five solutions varying in concentration from 1 to 5
mM solutions of each contrast agent in PBS. The factory installed inversion recovery
pulse sequence was used with the following parameters: Recycle delay ≥10 × T1; number
of data points = 16; number of averages = 4; inversion pulse delay times ranged from 2
ms to 2500 ms (0.47 and 1.41 T) and 10 ms to 5000 ms (9.4 and 14.1 T). Relaxation time
constants were determined by averaging the values obtained from six measurements for
each concentration.
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7.6.4. Chapter 5. Effect of rotational correlation time (τR) on rotating frame
longitudinal relaxivity (r1ρ)
NMRD profiles were generated from laboratory frame relaxivity determinations of
nanoassembled capsules (NACs) prepared at charge ratios (R) of 0.3, 0.5 and 1 in water
at the four magnetic field strengths studied (0.47, 1.41, 9.4 and 14.1 T, R = 0.3 only
performed at 0.47 T). Rotating frame relaxivity determination for the same samples
could only be determined at 9.4 and 14.1 T (R = 0.3 only performed at 14.1 T) due to
instrument limitations which limits the maximum spin lock pulse duration to 40 ms,
insufficient time to observe complete relaxation with the sample concentration available.
NMRD profiles were also generated from the laboratory and rotating frame relaxivity
determinations of the free GdDOTP5- chelate in water at the four magnetic field strengths
studied (0.47, 1.41, 9.4 and 14.1 T). Relaxivities were determined by linear regression
analysis of the longitudinal relaxation rate constant as a function of Gd3+ concentration in
Excel. The aqueous suspension of NACs was mixed thoroughly in the NMR sample tube
prior to each experiment and allowed to equilibrate to the set sample temperature for at
least 5 minutes.

This was repeated for each repetition to minimize errors in the

measurement due to settling of the NACs in the tube.
Rotating frame longitudinal relaxation rate constants (R1ρ) for NACs were determined on
four solutions in water. The concentrations varied between 0.028 – 0.98 mM (9.4 and
14.1 T).
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For the free chelate five solutions were used varying in concentration from 10 – 25 mM
(0.47 and 1.41 T) and 1 – 5 (9.4 and 14.1 T). The factory installed spin locking pulse
sequence was employed with the following pulse sequence parameters; recycle delay ≥
10 × T1; number of data points = 16; number of averages = 4; spin locking pulse
durations for GdDOTP5- ranged from 2 – 40 ms with a Rabi frequency (ω1) = 35 kHz
(0.47 and 1.41 T) and 5 – 1500 ms with a Rabi frequency (ω1) = 6924.2 and 17237.0 kHz
(9.4 and 14.1 T respectively). For NACs the spin locking pulse durations ranged from 4
– 400 ms with a Rabi frequency (ω1) = 6924.2 and 17237.0 kHz (9.4 and 14.1 T
respectively).

Relaxation time constants were determined by averaging the values

obtained from three measurements for each concentration.
Laboratory frame longitudinal relaxation rate constants (R1) for NACs were determined
on four solutions in water. The concentrations varied between 0.028 – 0.73 mM (0.47
and 1.41 T) and 0.22 – 0.98 (9.4 and 14.1 T) whereas for the free chelate five solutions
were used varying in concentration from 1 – 5 mM at all four fields studied (0.47, 1.41
9.4 and 14.1 T). The factory installed inversion recovery pulse sequence was used with
the following parameters: recycle delay ≥10 × T1; number of data points = 16; number of
averages = 4; inversion pulse delay times for GdDOTP5- ranged from 1 – 4000 ms (0.47
and 1.41 T) and 10 – 5000 ms (9.4 and 14.1 T). For NACs the inversion pulse delay
times ranged from 12.5 – 4000 ms (0.47 and 1.41 T) and 10 – 10000 ms (9.4 and 14.1 T).
Relaxation time constants were determined by averaging the values obtained from three
measurements for each concentration.

CHAPTER 7. Experimental

136

7.6.5. Chapter 6. Effect of hydration state (q) on rotating frame longitudinal relaxivity
(r1ρ)
NMRD profiles were generated from laboratory and rotating frame relaxivity
determinations of each chelate investigated (MnEDTA, MnCl2, GdTTHA3-, GdDTPA
and GdCl3) in PBS pH 7.4 at the four magnetic field strengths studied (0.47, 1.41, 9.4 and
14.1 T). Relaxivities were determined by linear regression analysis of the longitudinal
relaxation rate constants as a function of contrast agent concentration in Excel.
Rotating and laboratory frame data for GdDTPA (Magnevist) were obtained from
previous experiments for which experimental details have been described vide supra
(7.6.3).
Rotating frame longitudinal relaxation rate constants (R1ρ) were determined on five
solutions of MnEDTA, MnCl2 and GdCl3 varying in concentration from 5 – 25 mM (0.47
and 1.41 T) and 1 – 5 mM (9.4 and 14.1 T) with the exception of GdCl3 at 14.1 T which
was measured from four solutions. GdTTHA3- R1ρ values were obtained from a single
point determination with solution concentrations of 80.53 mM (0.47 and 1.41 T) and
4.026 mM (9.4 and 14.1 T). The factory installed spin locking pulse sequence was
employed with the following pulse sequence parameters; recycle delay ≥ 10 × T1; number
of data points = 16; number of averages = 4. Spin locking pulse durations for MnEDTA,
MnCl2 and GdCl3 ranged from 0.5 to 40 ms (0.47 and 1.41 T) and 1 – 400 ms (9.4 and
14.1 T) and the Rabi frequency (ω1) = 35 kHz (0.47 and 1.41 T) and 6924.2 and 17237.0
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kHz (9.4 and 14.1 T respectively). For GdTTHA3- the spin locking pulse durations
ranged from 0.5 to 40 ms (0.47 and 1.41 T) and 5 – 1500 ms (9.4 and 14.1 T) and the
Rabi frequency (ω1) = 35 kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 kHz (9.4 and
14.1 T respectively). Relaxation time constants were determined by averaging the values
obtained from six measurements (three for GdTTHA3-) for each concentration.
Laboratory frame longitudinal relaxation rate constants (R1) were determined on five
solutions of MnEDTA, MnCl2 and GdCl3 varying in concentration from 1 – 5 mM (0.47,
1.41 T, 9.4 and 14.1 T) with the exception of GdCl3 14.1 T which was measured from
three solutions. GdTTHA3- R1 values were obtained from a single point determination
with solution concentrations of 80.53 mM (0.47 and 1.41 T) and 4.026 mM (9.4 and 14.1
T). The factory installed inversion recovery pulse sequence was used with the following
parameters: recycle delay ≥10 × T1; number of data points = 16; number of averages = 4.
Inversion pulse delay times for MnEDTA, MnCl2 and GdCl3 ranged from 1 – 5000 ms
(0.47 and 1.41 T) and 6 – 6600 ms (9.4 and 14.1 T). For GdTTHA3- the inversion pulse
delay times ranged from 1 – 5000 ms (0.47 and 1.41 T) and 10 – 3000 ms (9.4 and 14.1
T). Relaxation time constants were determined by averaging the values obtained from six
measurements (three for GdTTHA3-) for each concentration.
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APPENDIX: T1 AND T1ρρ TIME CURVES AT 1.41 T (60 MHz) AND 37 °C
(APPENDIX TO CHAPTER 2).
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Figure A1.1: Effect of delibarate variations to the relaxation delay (RD) time on T1 time curves
(inset shows deviation (squares) when relaxation delay is < 10 x T1). Sample: PBS pH 7.4
solution of Dotarem, [Gd3+] = 25 mM. n = 1.
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Figure A1.2: Effect of deliberate variations to the relaxation delay (RD) time on T1ρ time curves.
Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.
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Figure A1.3: Effect of deliberate variations to the first pulse delay time (τ) on T1 (a – c) and T1ρ (d
– g) time curves. Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.
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Figure A1.4: Effect of deliberate variations to the last pulse delay time (τ) on T1 (a – c) and T1ρ (d
– e) time curves. Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.
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Figure A1.5: Effect of deliberate variations to the number of data points on T1 (a – d) and T1ρ (e –
h) time curves. Sample: PBS pH 7.4 solution of Dotarem, [Gd3+] = 25 mM. n = 1.

